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Executive summary 
 
Plants may serve as new hosts for the production of recombinant nutraceuticals and 
pharmaceuticals. Nutraceuticals and pharmaceuticals can be distinguished at best on 
the basis of their aim.  
 
Nutraceuticals on the one hand aim to maintain the health situation of principally 
healthy humans or animals. They are single compounds that are naturally present in, 
or (purified) added to foods for daily consumption. Such foods are called 'functional 
foods' (and in the case of animal application: 'functional feed'). They can be supplied 
with a health claim. 
 
Pharmaceuticals on the other hand aim to cure (human, animal) patients, to mitigate, 
or to serve in diagnostics. They are purified, well defined medicinal and/or therapeutic 
preparations that have passed the clinical tests and that are supplied with a medicinal 
claim.  
 
Plants, transgenically producing nutraceuticals or pharmaceuticals, should meet the 
general requirements for genetically modified organisms, and, additionally, the 
specific requirements related to the production of the specific medicinal or health 
compounds. To guarantee safety, to proper regulate the production processes, and for 
the sake of consumers trust, in the EU and USA, an extensive variety of (often region-
specific) guidelines and regulations encircle both categories of activities, the GM 
technology, and the production of health foods and medicinal articles:  
 
?? For the cultivation, import, marketing and animal feeding of a genetically 
modified crop approval must be sought from the EU. A distinction is made by 
Dutch legislation between the in-doors- and out-doors- cultivation of genetically 
modified plants. The in-doors cultivation, will require a less elaborate risk 
assessment than the out-doors cultivation. 
 
?? Production of pharmaceuticals and nutraceuticals in GMOs in greenhouses is 
bound by special rules related to the transgenic status of the plants and should 
occur according to the guidelines for "good agricultural practice" (GAP). GAP 
guidelines apply to the production of all plant materials used in the food, feed , 
medicinal , flavoring and perfume industries. GAP conditions must also be met 
concerning processing of the harvested transgenic plant material. The type of 
greenhouse (PK-I, PK-II or PK-III) that needs to be used depends on the the 
specific case and is related to the characteristics of the inserted gene, the 
biological and agronomic characteristics, and the treatments of the crop plant 
involved.  
 
?? Food applications include whole foods and food ingredients on one side and food 
additives on the other side. Both categories are differently regulated. In the EU, 
genetically modified organisms are regulated as a specific category for use as 
novel foods or novel- food ingredients but not for use as food additives, colourants, 
or flavourings. 
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?? Foods that are considered safe can eventually be accommodated into foods for 
special dietary uses. Both in the EU and USA, these dietary foods are specifically 
regulated. 
 
?? With regard to food supplements, the EU limits its scope to vitamins, minerals, 
and herbal extracts, whereas the scope of the American legislation is less narrow. 
 
?? Different national regulations exist in the EU on the use of food-related health 
claims, as no EU-harmonisation has been reached yet. In The Netherlands, where 
health claims are voluntarily verified, three institutions are active in this field. In 
the USA, regulations on health claims are somewhat different for foods and food 
supplements. 
 
?? Both for food-, feed-, and pharmaceutical- production, requirements have been 
formulated for “good manufacturing practices” (GMP) in The Netherlands and 
abroad. 
 
?? With regard to the patenting of genetically modified plants, there are some 
restrictions, such as the exclusion of plant varieties from patentability. 
 
?? Marketing approval of human and veterinary medicines will require a prior pre-
clinical and clinical testing of the pharmaceutical to demonstrate its effectiveness 
and safety. In general, a “short-cut” approval procedure can be followed if a 
medicine is equivalent to a previously approved medicine. In the EU, however, 
biotechnology-derived pharmaceuticals will always have to go through the full 
procedure, contrary to the shorter procedures for some “bio-equivalent” medicines 
in the USA. Medicines are available either on prescription or “over the counter”. 
 
A hypothetical case is discussed that serves as a model for crops that are enhanced 
with components of pharmaceutical interest, namely a crop expressing recombinant 
“follicle stimulating hormone” (FSH). Preparations containing FSH for human and 
veterinary use that are currently in the market are produced either from body fluids or 
from genetically modified hamster cells. 
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1. Introduction 
 
1.1 Nutraceuticals and pharmaceuticals: current developments 
 
During the last decade, many millions of hectares have been planted worldwide with 
transgenic crops. Over 90% of these crops provide transgenically the agronomic 
properties of herbicide and pest tolerance. Currently, a new phase in genetic 
modification is beginning. This phase can be considered the engineering of plants, not 
for the improvement of their agronomic properties, but to make new or improved 
products. This development enables farmers to produce higher-value products, for 
food and feed, for medical and for industrial objectives, and is expected to have a high 
economic impact. In this report we focus on the exploitation and regulatory aspects of 
the transgenic production of health foods and feeds, and pharmaceutical products.  
 
Genetic modification of plants has provoked lots of discussions on safety. This has 
resulted in national and international regulations on field releases and market 
introductions. The production and marketing of medically related products has already 
been encircled by requirements and regulations for a longer time. Entering the new 
phase of engineering plants for health and medical purposes, there is a need for the 
evaluation and attunement of regulations and requirements from the GMO and the 
medical/health side along the entire production chain.  
 
1.2. About the report 
 
Initially, there were discussions within the project group about the borders between 
health food and medicines. A grey area seemed to exist between the two fields of 
production and products, where both deal with the production of compounds that are 
physiologically active in human or animals. From these discussions it has been 
concluded to prepare in the report a separate chapter (Chapter 2) that is introductory 
to the next chapters. In this chapter definitions and descriptions are given of the terms 
'pharmaceutical', 'nutraceutical', 'functional food', etc. 
 
The regulatory apects involved in the production of nutraceuticals and 
pharmaceuticals form the essential and most substantial part of the present report 
(Chapter 3). The current state has been elaborated and extensive comparisons have 
been presented about the relevant regulations in the EU and USA on GMOs on the 
one hand, and on pharmaceuticals for human and veteriary use, nutraceuticals and 
functional foods on the other hand. Where relevant, the specific Dutch situation is 
indicated. Further attention has been given to the manufacuring practice conditions 
throughout the production chain. Also the requirements for the use of health claims 
have been dealt with, and the issue of patentability has been treated. The hypothetical 
example of the production of recombinant FSH, given in Chapter 6, clearly indicates 
the regulatory issues that have to be considered. 
 
Chapter 4 summarises biosafety considerations of transgenic plants producing 
functional foods, nutraceuticals, and pharmaceuticals. 
 
Chapter 5 gives the details on the legal requirements for a greenhouse to be used for 
the production of pharmaceuticals, nutraceuticals and functional foods, including 
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guidelines for "good agricultural practice" and "good manufacturing practice" (GAP 
and GMP, respectively) and the required degrees of physical containments in different 
greenhouse applications.  
 
Concluding and summarizing remarks are made and regulatory options are given in 
Chapter 7. The case-by-case approach to biosafety, containment aspects, post-market 
surveillance in the case of out-doors cultivation, and options for contained culture 
have been given attention. Also the two cases have been shortly evaluated in this last 
chapter. 
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2. Definitions and Descriptions  
 
2.1. General  
 
In common literature, nutraceuticals and pharmaceuticals are often mentioned in one 
breath. The reason is that these products have physiological activity in human and 
animals, and all are related to health in its broadest sense. Irrespective of their exact 
definition, nutraceuticals and pharmaceuticals can be distinguished at best on the basis 
of their direct aim: is the product a food, or is the product a medicine. Nutraceuticals 
aim at maintenance of the health situation of healthy individuals. Nutraceuticals add 
health promotion to the regular function of a foodstuff being a source of building 
material and energy. Nutraceuticals are available over the counter, e.g. in a 
supermarket, and can be consumed as part of the daily diet. Pharmaceuticals are 
produced to cure human or animal individuals, for mitigation or for diagnostics and 
are generally available from a doctor or veterinary surgeon. Some pharmaceutical 
products, especially those for mitigation and self-diagnostic purposes, are freely 
available. 
 
The aims and controlled availability make the position in daily life of pharmaceuticals 
clear, in contrast to the position of nutraceuticals. Pharmaceuticals are medicinal 
preparations. Their effects and side-effects in human and animals must be known 
exactly from medical and veterinary trials. Nutraceuticals have primarily to be proven 
safe-to-eat; of many nutraceuticals, the beneficial activity as such has not been 
demonstrated unambiguously. For the purpose of this report, more elaborate 
definitions and descriptions on production and application of the various types of 
products are given below. 
 
2.2. Nutraceuticals, functional foods and functional food crops 
  
2.2.1. Definitions  
 
Confusing terminologies 
 
There is a lot of terminology around nutraceuticals which may raise considerable 
confusion as will be shown in this paragraph. Synonymous to, or belonging to the 
same field of terminology of ‘nutraceuticals’ are ‘functional foods’, 'designer foods', 
‘positive nutrition’, 'foods with dietary supplements’, 'foods with functional 
ingredients', 'health food', 'dietary food', 'fuctional food ingredient', etc. Nutraceuticals 
are colloquially understood as a product that can be a single well-defined food 
compounds with health promoting characteristics, but also as complex foods with 
such beneficial characteristics. Neutraceuticals may be briefly and meaningless 
defined as 'nutritionally or medicinally enhanced foods' (Brower, 1998), whereas 
other authors give more extended descriptions. Anyway, the term 'nutraceutical' 
originates from DeFilice (1979), founder of the Foundation for Innovation in 
Medicine. He defined nutraceutical as: 'food, or part of food, that provide medical or 
health benefits, including the prevention and treatment of disease' (quoted in Brower, 
1998). The first part of this definition relates to a complete (complex) food produc t or 
a single compound. The latter part makes a nutraceutical similar to a pharmaceutical. 
On the other hand, Schaafsma (1994) defines ‘nutraceutical’ (written as nutriceutical) 
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in a narrower sense as the specific purified or extracted food supplement, tha t is also 
available separately (encapsulated) from a drug store or a reform shop (over the 
counter). Examples are vitamins, minerals, unsaturated fatty acids, milk proteins, etc. 
Further he defines foods supplemented with specific nutraceuticals to meet a 
particular objective as ‘designer foods’, whereas ‘functional foods’ include all health 
promoting foods with ‘designer foods’ among them (Schaafsma, 1994). Different 
definitions distinguish between nutraceuticals, as food products that function as (and 
therefore substitute) pharmaceuticals, and functional foods, as foods with human 
health enhancing qualities (Bijman, 1999). The problem is that these terminologies 
and definitions blur the border between foods and medicins. Such situation should be 
prevented.  
 
Defining nutraceuticals, functional foods, and pharmaceuticals 
 
For the purpose of clarity in the present report, we would suggest to limit the 
terminology to the following used by Health Canada as working definitions (Health 
Canada, 1998): 
?? A functional food is similar in appearance to, or may be, a conventional food, is 
consumed as part of a usual diet, and is demonstrated to have physiological 
benefits and/or reduce the risk of chronic disease beyond basic nutritional 
functions (Health Canada working definition) 
?? A nutraceutical is a product isolated or purified from foods that is generally sold 
in medicinal forms not usually associated with food and demonstrated to have a 
physiological benefit or provide protection against chronic disease (Health Canada 
working definition) 
 
The definition for a functional food is very similar to that formulated by the EU 
funded Concerted Action on Functional Food Sciences in Europe (FUFOSE), namely 
“foods that have been satisfactorily demonstrated to affect beneficially one or more 
target functions of the body, beyond adequate nutritional effects, in a way which is 
relevant to either an improved state of health and well-being, or reduction of the risk 
to diseases”. The “adequate nutritional effects” are basic needs defined by the 
recommended daily intakes, e.g. for vitamins (Diplock et al., 1999; ILSI, 1998). 
 
In addition to the definition for a functional food, “functional feed” and “functional 
crop” are used with similar meanings. 
 
The Canadian working definition for a nutraceutical is similar to that of Schaafsma 
(1994). In this report, the definition for nutraceutical is used also for purified 
substances that are added to foods. The inclusion of a nutraceutical in a food may 
render it a functional food based on the health-beneficial properties of the 
nutraceutical. 
 
These definitions will be used as “working definitions” throughout this report. It 
should be noted that they are not legal definitions themselves, and the products 
defined by these working definitions may fall under various legal definitions, 
depending on the scope of their application (see section 3.1). 
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2.2.2. Production 
 
Approaches  
 
A food can be made a functional food by using different approaches (FUFOSE, 
1999): 
?? to eliminate a component known to cause deleterious effects to the consumer (e.g. 
an allergenic protein), 
?? to increase the concentration of a natural component in food, 
?? to add a component which is not normally present in most foods, but for which 
beneficial effects have been demonstrated (e.g. non-vitamin anti-oxidants, or 
fructans), 
?? to replace a component, usually a macronutrient, the intake of which is usually 
excessive (e.g. fats) by a component which has beneficial effects (e.g. 
oligosaccharides), and 
?? to improve the bioavailability of, or to modify, food components for which 
beneficial effects have been demonstrated 
 
Role of genetic modification 
 
For several of the approaches given above, genetic modification can be used to 
improve a food crop directly into a functional food crop:  
?? antisense technique for elimination of health- impairing proteins; 
?? overexpression to increase the concentration of specific functional ingredients; 
?? introduction of a new metabolic pathway or side chain; 
?? blocking of a metabolic pathway. 
 
Interesting opportunities for nutraceuticals 
 
Compounds with health promoting properties that can be considered for inclusion into 
a nutraceutical or a functional food are, for example, flavonoids, carotenoids, 
unsaturated fatty acids, oligosaccharides, fibres, and minerals. Flavonoids may inhibit 
the development of cancer and arteriosclerosis. Carotenoids can scavange toxic 
oxygen radicals and function as provitamins. Multiple unsaturated fatty acids may 
prevent heart and vascular diseases. Oligosaccharides and fibres can bind toxic 
compounds and may serve as food for, and this way improve the quantity and quality 
of, the intestinal flora. Oligosaccharides and fibres are poorly digestible and are 
therefore helpful in keeping the dietary energy low. In addition, health effects have 
been attributed to minerals, including the minerals calcium (bone development), 
selenium (as an anti-oxidant) and iron (to prevent anaemia) (Helsper, 1998). 
Increasingly, transgenic research in plants is directed to engineer the relevant 
metabolic pathways (Dixon & Arntzen, 1997; Hammond et al., 1999; Ohlrogge, 1999; 
Willmitzer, 1999; Schmidt-Dannert et al., 2000).   
 
The market  
 
Functional foods and nutraceuticals are becoming more and more popular with 
consumers who desire to influence their own health and well-being through their diet. 
On the other side, there are the food producing industries that experience new market 
niches for their products when they are upgraded to a functional food. The scientific 
Exploitation and regulation of plants genetically modified to express nutraceuticals and 
pharmaceuticals  
http://www.rikilt.wageningen-ur.nl/nutraceuticals  
 14
basis for the application of functional foods is much less clear than that of 
(recombinant) pharmaceuticals and (genetically modified) medicinal (food) plants. At 
present, for most existing functional foods adequate scientific bases for their health 
benefits are lacking. 
 
2.2.3. Health claims 
 
Nutraceuticals and functional foods both have, by definition, positive effects on 
consumers’ health. The issue of health claims that are attached to these products is 
therefore important. The specific requirements for health claims are detailed in 
Section 3.3.4. In short, there is no law in The Netherlands on the use of health claims, 
but voluntary procedures have been installed by three institutions that are active in 
this field. Important in this respect is the weight of scientific evidence that can be 
provided in support of the health claim (Diplock et al., 1999). 
 
In the EU, the concerted action FUFOSE has been established to assess critically the 
scientific base required  
?? to provide evidence that specific nutrients positively affect target functions in the 
body; 
?? to examine the available sciences from a function driven point of view rather than 
a product-driven one; and 
?? to reach consensus on targeted modifications of food and food constituents, and 
options for their applications.   
 
2.3. Pharmaceuticals and medicinal plants  
 
2.3.1. Definitions  
 
Pharmaceuticals are single, well-defined medicinal and therapeutic compounds that 
are administered with the purpose to cure, mitigate, or diagnose disease. Similar 
compounds for veterinary application are also categorized to pharmaceuticals. 
Medicinal plants are plants that produce pharmaceuticals naturally.  
 
2.3.2. Production  
 
Pharmaceuticals can be produced chemically, or biologically by micro-organisms, 
animal cell cultures, and plants. In these biological systems, the pharmaceutical can be 
a natural product, or can result from genetic modification. Plants are one of the new 
hosts that can serve for the production of recombinant pharmaceuticals. Biologically 
produced pharmaceuticals are often indicated as biopharmaceuticals (Miele, 1997). In 
this report we will use the term pharmaceuticals, referring only to the function of the 
compound and not to the (biological) way of production.  
 
Recombinant pharmaceuticals in crop plants 
 
Currently, the production of recombinant pharmaceuticals in crop plants includes 
especially proteinaceous compounds such as hormones, antibodies, plasma proteins, 
enzymes and vaccines. The production of oral vaccines with transgenic crop plants 
offers the advantage that the crop needs not be purified to be consumed as a vaccine, 
such as raw tomatoes and bananas. Such specialty crops enable to combine 
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experiences from the production of pharmaceuticals in microbial and animal cell 
production systems with experiences on the genetics and agricultural characteristics of 
the crop involved, including the typical biological and production characteristics. As 
for other genetically modified crops (such as those producing nutraceuticals), human 
and environmental safety during production must be assessed before such plants can 
be approved as specialty crops in agriculture (greenhouse or open field). Such 
assessment will show which concerns have practical relevance, and enables to set up 
strategies to deal with these concerns. Risk assessments on genetically modified crops 
in general, including pharmaceutical-producing plants, always need a case-by-case 
approach (see Chapter 4) using sound scientific and clinical judgement. For the large-
scale agricultural production of recombinant pharmaceuticals, the choice of plant 
species, geographic location of test plots and production fields, the choice for 
production under contained greenhouse conditions, and monitoring protocols are 
essential to prevent adverse consequences (Miele, 1997; Hammond et al. 1999). The 
legal requirements that regulate such choice are given in the next chapter.   
 
Purification 
 
With a qualified harvest of plant material (e.g. seeds), the challenge is to convert an 
agronomical commodity into a pharmaceutical, that is essentially identical to the same 
product from any other production system. This requires every step in the production 
process to be described as good manufacturing practice (GMP) (Section 3.6.4 and 
Chapter 5). 
 
Recombinant nutraceuticals and pharmaceuticals 
 
Comparing recombinant nutraceuticals and pharmaceuticals produced in plants, the 
nutraceuticals are often products from the primary or secondary metabolism of the 
plant cell whereas pharmaceuticals may also consist of proteinaceous compounds 
directly resulting from an introduced single transgene. Metabolic pathway engineering 
in plants will in future enable to produce exotic and rare compounds at increased 
scales.  
 
Medicinal plants 
 
Medicinal plants are known from a long history. Many plant species have been named 
according to some medical application such as 'Hepaticae' (liver mosses) as old 
medicine against liver diseases. And a common species name of many plants is 
'officinalis' which refers to medical application. About one-third of medicines used 
today are derived from plants, with aspirin, morphine, artemisin and taxol as well-
known examples. 
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3. Regulations and Registrations 
 
3.1. General 
 
The scope of this report covers the production of physiologically active compounds 
by genetically modified plants. Three possibilities are considered here for the novel 
product derived from genetically modified plants: 
1. The product is a “functional food / feed / crop plant”; the product is used 
for food purposes (food, food ingredient, a dietary food) or animal feed 
purposes (feed, feed ingredient). 
2. The product is a “nutraceutical”; the product is used for food purposes 
(food ingredient, food additive, food supplement) or animal feed purposes 
(feed ingredient, feed additive). 
3. The product is a pharmaceutical and is used as a medicinal preparation. 
 
For the various shapes that the novel product from a genetically modified plant may 
take within any of these possibilities, different regulations apply both in the EU and 
the USA. These regulations, which are detailed below, determine how dossiers should 
be prepared with regard to, for example, safety tests on- and manufacturing conditions 
of- the product. These dossiers are submitted to the competent authorities for review. 
Table 1 summarises the product opportunities that we describe for a functional food / 
feed / crop plant, nutraceutical, or pharmaceutical in the EU and the USA. 
 
Throughout the text, references are made to EU-, Dutch-, and American- legislation. 
Most of these references can be retrieved through the Internet: 
?? EU: http://europa.eu.int/eur- lex/en/search_lif_simple.html. 
?? Netherlands: http://www.minvrom.nl/minvrom/pagina.html?id=1&goto=1489. 
?? USA: http://www.fda.gov/opacom/laws/lawtoc.htm and 
http://www.epa.gov/epahome/lawreg.htm. 
 
The Dutch legislation is discussed as far as there are relevant differences from EU 
legislation that would affect the envisioned applications of a novel product derived 
from a genetically modified plant. 
 
 
The applications of functional foods, functional feed, and purified nutraceuticals that 
are possible within the EU-, and American- regulatory framework are summarised in 
Table 1. 
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Table 1 Applications envisioned for a functional food, nutraceutical, or 
pharmaceutical in the EU and the USA 
 
 functional food / feed 
/ crop plant 
(purified) 
nutraceutical 
pharmaceutical 
       
Food uses       
Food, whole EU USA     
Food ingredient EU USA EU USA   
Food additive 1  USA EU USA   
Food supplement  USA EU USA   
Food for special uses EU USA     
       
Feed uses       
Feed & feed 
ingredient 
EU USA EU USA   
Feed addit ive 1  USA EU USA   
       
Medicinal uses       
Medicine, human     EU USA 
Medicine, veterinary     EU USA 
 
1 “additive” is defined differently in the EU and the USA 
 
 
3.2. Cultivation and import of genetically modified crops and –crop 
products 
 
Only cultivation in the EU is considered here. 
 
3.2.1. Field trials 
 
EU  
 
Permission shall be sought for field trials, for which a dossier will be forwarded to the 
national authority. Such a dossier contains, among others, data on environmental- and 
human-health- risks of the GM plant. This dossier is reviewed by the national 
authority, which keeps the European Commission informed about the application, as 
specified under Part B of EU Directive 90/220 on the environmental release of 
GMOs. EU Directives have to be implemented by EU Member States, including The 
Netherlands, but leaves room for national adaptations of these Directives. 
 
Netherlands 
 
The notifier of an application for the large-scale-experimental release of a genetically 
modified plant is required to compile a more elaborate dossier on its molecular 
characteristics and its safety to the environment and, if applicable, animals and/or 
humans similar to that under part C of EU Directive 90/220 (See section 3.2.2). 
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3.2.2. Commercial cultivation 
 
For the commercial release of a genetically modified crop, permission at an EU level 
should be sought. The notifier is therefore required to supply details, among others, on 
the DNA insert, expression levels of transgenic proteins, composition of the 
transgenic plant, and safety of the transgene product, including data from field trials. 
Commercial releases are regulated by EU Directive 90/220, Part C, under which an 
application has to be submitted to a national authority and subsequently to the 
European Commission (Figure 1). A guidance document on dossier preparation has 
been issued by the Scientific Committee on Plants of the European Commission 
(SCP, 1998).  
 
EU Directive 2001/18, which will replace EU Directive 90/220 in the year 2002, has 
recently been adopted. The amendments include, among others, the requirement for 
post-marketing monitoring, the compulsory labelling of the genetically modified 
products, and the availability of detection methods for the genetically modified plant. 
In addition, genetically modified plants that are intended for production of medicinal 
products will be exempted from the risk assessment under EU Directive 90/220 (EP, 
2001a). 
 
3.2.3. Import of genetically modified crops or crop products 
 
EU 
 
The import of viable genetically modified products requires the market approval 
under EU Directive 90/220, part C. If the imported product is to be used as food or 
food ingredient, additional permission for food use shall be sought under the EU 
Regulation 258/97 for Novel Foods. 
 
USA 
 
The import-, movement between States-, and the environmental release- of genetically 
modified plants and seeds come under the scrutiny of the Animal- and Plant- Health 
Inspection Service (APHIS), which resorts under the U.S. Department of Agriculture 
(USDA). Considered, among others, will be the GMO’s potential to become a plant 
pest (Vogt and Parish, 1999). The import of genetically modified foods and feeds fall 
under the regulatory oversight of the Food and Drug Administration (FDA). 
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applicant 
member state 
application with dossier 
favourable opinion 
European Commission & member states 
no objections: 
marketing approval 
objections 
Council of Ministers 
opinion 
European 
Commission 
favourable opinion European Commission 
unfavourable opinion 
scientific committee 
decision 
Figure 1 Procedure for market approval of a genetically modified crop 
under EU Directive 90/220 (EU, 2000) 
draft decision 
regulatory 
committee 
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3.2.4. Contained use 
 
EU 
 
EU Directive 90/219 focuses on the use of genetically modified micro-organisms 
within a contained facility, such as a fermentor in a factory. This may include 
genetically modified eukaryotic cells, such as plant cells. The dossier that should be 
turned in for approval must contain, among others, molecular data on the transgenic 
insert and data on the organism’s safety. This directive may be relevant for those 
applications that involve the use of a plant cell culture for the production of 
metabolites. These metabolites should then be purified before being shipped from the 
factory, i.e. without the genetically modified plant cells. Self-cloned micro-organisms 
that contain inserted self-DNA are exempt from this directive, in other words they are 
not considered genetically modified. 
 
Greenhouse cultivation of genetically modified plants can be regarded “contained 
use” too if conditions are similar to “containment” of genetically modified cells 
described above, as stated in the recently amended EU Directive on genetically 
modified plants (EP, 2001a). 
 
Netherlands 
 
Greenhouse cultivation of genetically modified plants is regulated by the Dutch 
Decision on Genetically Modified Organisms (“Besluit Genetisch Gemodificeerde 
Organismen”). The requirements for greenhouse facilities are described in Chapter 5. 
 
3.3. Food uses 
 
3.3.1. Food, food ingredients, and food additives 
 
EU 
 
A food or food ingredient derived from a genetically modified organism is considered 
“novel” in the EU. Other foods considered “novel” in the EU are foods that have not 
been previously consumed within the EU, derived from micro-organisms, 
significantly altered, or processed in novel ways. Novel foods should be evaluated for 
market approval under EU Novel Food Regulation 258/97. Please note that viable 
genetically modified products need an approval for marketing under EU Directive 
90/220 prior to an approval for food applications under the Novel Food Regulation. 
 
The “authorisation” procedure for market approval under the EU Novel Food 
Regulation 258/97 is very similar to that under EU Directive 90/220. There is, 
however, an additional short-cut route of “notification” (Figure 2). In the case of 
“notification”, the applicant supplies evidence for the “substantial equivalence” (see 
below) of a product derived from genetically modified organisms to a conventional / 
commercial counterpart. Notifications that have led to market approvals include those 
for processed oil from genetically modified canola and products, such as starch and 
oil, from genetically modified maize kernels (EU, 2000). 
 
Exploitation and regulation of plants genetically modified to express nutraceuticals and 
pharmaceuticals  
http://www.rikilt.wageningen-ur.nl/nutraceuticals  
 22
For the “authorisation” procedure, decision trees will provide guidance on the data 
required for compiling the dossier (EU, 1997). In all cases, information should be 
provided on the toxicological and microbiological safety of the novel food, in addition 
to its nutritive value and its estimated intake. 
 
Substantial equivalence is the central principle in the assessment of the safety of a 
genetically modified crop, based upon which it is decided which safety tests will be 
required. The submitted crop or its products are substantially equivalent to a 
conventional counterpart if they are phenotypically and compositionally comparable. 
In that case, no further safety testing would be required under the present policy.  
 
If, however, the crop or product is substantially equivalent except for one or a few 
compounds, the toxicological significance of the altered compounds should be 
assessed. Crops or foods/feeds that are not substantially equivalent at all should be 
submitted to a full safety test. 
 
Food additives are defined as substances that do not occur normally in consumed 
foods, excluding, however, flavourings and, in general, nutrients (minerals, vitamins). 
Extensive safety testing will therefore be required before a food additive will receive 
market clearance under EU Directive 89/107. If, by coincidence, the nutraceutical 
possesses sensory properties, it may be used as a food flavour. Flavourings are used to 
add odour or taste to foodstuffs. Several substances are allowed as such under EU 
Directive 88/388, including substances isolated from vegetable tissue by physical 
means. Specific permissible food uses of sweeteners, colourants, and other additives 
are described by EU Directives 94/35, 94/36, and 95/2. 
 
For additives and flavourings to be approved, no distinction is made in EU legislation 
for substances derived from genetically modified organisms. 
 
Foods and genetically modified foods containing detectable transgenic proteins or -
DNA should be labelled under EU Regulation 49/2000. The same applies to 
foodstuffs containing additives or flavourings derived from genetically modified 
organisms under EU Regulation 50/2000, provided the additives or flavourings have 
been released on the market after April 2000. 
 
USA 
 
Genetic modification is not considered different from other technologies for crop 
improvement in the USA. American legislation is therefore oriented to the safety 
evaluation of the altered characteristics of the genetically modified food (FDA, 1992). 
Newly expressed gene products may be regarded “food additives” or “pesticide 
products” and should therefore be evaluated for their food safety. Food additives are 
evaluated by the FDA and pesticide residues by the Environmental Protection Agency 
(EPA) (Vogt and Parish, 1999). Please note that the American definition of a “food 
additive”, i.e. “not generally recognised as safe” (non GRAS, see below), is different 
from that in the EU. On the other hand, GRAS status may be sought for foods with 
altered compositions, i.e. a vegetable oil with a changed fatty acid profile. 
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Figure 2 Procedure for market approval of Novel Food under 
EU Regulation 258/97 (EU, 2000) 
applicant 
application for authorisation 
member state 
favourable opinion 
European Commission & member states 
no objections: 
marketing approval 
objections 
similar procedure as under 90/220 
notification of substantial equivalence 
European Commission member state 
positive opinion marketing approval 
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American food additives should always be evaluated for their safety by the FDA, 
while other foods and food ingredients should be “generally recognised as safe” 
(GRAS) under the Federal Food Drugs and Cosmetics Act (FFDCA). The 
determination of GRAS status by the FDA is not mandatory. Moreover, a food 
substance can be declared “GRAS’ by its manufacturer (“GRAS self-determination”). 
In practice, however, the market will only accept GRAS determinations that are 
endorsed by recognised institutions in order to avoid legal liability for the use of food 
substances that may turn out to be unsafe. These recognised institutions include the 
FDA itself, but also “extramural” associations such as the Federation of American 
Societies for Experimental Biology (FASEB) and the Flavor and Extract 
Manufacturers’ Association (FEMA) (Institute of Medicine, 1999). The procedure for 
food additive petitions is more tightly regulated than for GRAS status. The FDA’s 
Redbook lists the toxicological tests required for safety testing of food additives and –
ingredients (FDA, 2000a). 
 
Newly expressed gene products such as viral coat proteins, viral replicases, herbicide 
degrading enzymes and herbicide tolerant enzymes are regarded “plant pesticides”. 
These gene products are therefore evaluated by the EPA, which determines the 
pesticide levels that are tolerable in raw agricultural commodities (Code of Federal 
Regulations, Title 40, Part 180). The FDA will, in turn, accept the occurrence of these 
pesticides in food products, provided the pesticide levels in these products do not 
exceed the tolerable levels determined by the EPA. Transgenic proteins that have thus 
been tolerated by the EPA in commodities are, however, generally exempted from an 
upper threshold level of tolerance based on the absence of harm from the estimated 
human exposure to these pesticides, which are present at low levels in plants. 
 
The FDA recently made a proposal for new legislation, under which the notification 
of genetically modified food / feed crops by their manufacturers 120 days before 
market release will become mandatory. In addition, rules are developed for those 
producers that wish to label genetically modified foods / feeds voluntarily (FDA, 
2001a). 
 
3.3.2. Food for special uses 
 
EU 
 
Foods for infants, sportsmen, and hospitalised patients (e.g. enteral nutrition) are 
among the “foods with particular nutritional uses” as defined by the EU. Such foods 
should be labelled as “dietetic” or “dietary”. Special requirements for the levels of 
vitamins and minerals in infant formulae have been formulated in amendments to EU 
Directive 89/398, which regulates these types of food. 
 
USA 
 
Similar to the EU’s provisions for foods for particular nutritional purposes, the FDA 
has formulated requirements for the manufacturing-, composition-, and labelling- of 
“foods for special dietary use”, including infant formulae and weight- loss products 
(FDA, 2000b). In addition, “medical foods” for oral consumption or enteral nutrition 
have been defined by American law as foods that provide nutrients to people other 
than healthy, such as those with diseases or “distinctive nutritional requirements”. 
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Medical foods are exempt from the regulatory requirements for food labelling, 
including health claims (FDA, 2000c). 
 
3.3.3. Food supplements 
 
EU 
 
Food supplements are defined by the EU as concentrated forms of nutrients, which 
serve to supplement the dietary nutrient intake, such as vitamins, minerals, amino 
acids, fatty acids, fibre, and herbal- and plant extracts. An EU Directive on Food 
Supplements will likely enter into force in the near future, as a proposed version was 
recently adopted by the European Commission (EC, 2000a; EP, 2001b). For the time 
being, the directive gives a limited account of vitamins and minerals permitted to be 
sold as supplements. Requirements for other ingredients, such as plant and herbal 
extracts, are still to be defined. For those supplements that are not covered by EU 
Directives, national legislation of EU member states should apply (EP, 2001b). 
 
Purified vitamins and minerals can also be added to foods rendering these foods 
“fortified”. Member states’ regulations on food fortification have not been harmonised 
yet at an EU level. 
 
Netherlands 
 
Food supplements are considered “health products”, i.e. products that look like 
pharmaceuticals or that are linked to health-functions, but that are no medicines (see 
section 3.3.4). Similar to conventional foods, health products are regulated by the 
Commodity Act. Food supplements containing vitamins are more specifically 
regulated by the Commodity Act Rule waiving Vitamin Preparations 
(“Warenwetregeling Vrijstelling Vitaminepreparaten”) (Vroom Cramer, 1998). 
 
Food fortification is regulated by the Commodity Act Decision on the Addition of 
Micro-Nutrients to Foods (“Warenwetbesluit Toevoeging Micro-voedingsstoffen aan 
Levensmiddelen”). The addition of all micro-nutrients is permitted, except for iodine, 
fluorine, and amino acids. Three categories of food fortification with micro-nutrients 
are considered: 
?? Restoration: compensating for nutrient losses during food manufacture. 
?? Substitution: addition of nutrients of a product to a substitute for that product. 
?? Enrichment: addition of nutrients to products that do not contain them. 
Limits are posed to the added amounts of micro-nutrients, based on their 
recommended daily intakes. Fortified foods are allowed to bear claims pertaining to 
their nutrient contents (Vroom Cramer, 1998). 
 
USA 
 
American food supplements may consist of vitamins, minerals, herbs and dietary 
components as tablets, fluid or food. Food supplements are not allowed to be 
marketed as foods. Supplements are less stringently regulated as they fall under the 
Dietary Supplement Health and Education Act. Their constituents need not be GRAS, 
but the manufacturer should be able to prove their safety. In case the supplement 
contains a novel ingredient, the FDA should receive a notification and data 
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substantiating the novel ingredient’s safety 75 days prior to its market release (FDA, 
2001b) 
 
American legislation on food fortification is similar to that of the Netherlands (Code 
of Federal Regulations, Title 21, Part 104.20). 
 
International harmonisation 
 
In addition, efforts are made by the EU and the US to harmonise legal criteria for food 
supplements containing vitamins and minerals, in order to ensure marketability of 
these products in both regions. These criteria will include, among others, Good 
Manufacturing Practice (GMP) (TABD, 2000). 
 
3.3.4. Health claims 
 
EU 
 
A recent research report prepared by consultants of Hill and Knowlton analyses the 
current situation concerning the legislation of health claims on foodstuffs in the EU. 
For details on the different national procedures for health claims on foods and food 
supplements we refer to this study (Hill and Knowlton, 2000). In Hill and Knowlton’s 
report, three types of claims are discerned: nutritional-, health- and ethical claims. 
Nutritional claims pertain to the composition of the foodstuff, while health claims 
concern the potential health benefits of consumption. Ethical claims say something 
about the working conditions under which the food has been manufactured, such as 
for Dutch “Max Havelaar” products. 
 
Two directives are most tightly linked with food labelling, 2000/13 (labelling and 
advertising of food) and 90/496 (labelling of nutritional value). These directives are, 
however, not comprehensive on health claims. EU Directive 2000/13, for example, 
does only define those claims that are not permitted as follows: “The labelling and 
methods used must not … attribute to any foodstuff the property of preventing, 
treating or curing a human disease, or refer to such properties”. Hence genuine 
medicinal claims are not allowed on foods. This may change, however, as a recent 
resolution of the Euro-parliament attached a high priority to the inclusion of all 
labelling issues into one directive (EP, 2000a). 
 
EU Directive 90/496 regulates nutritional claims on labels. Such claims relate to the 
nutritional value of the foodstuff, such as the content of vitamins. It does not, 
however, specify rules for the evidence needed in support of such claims. 
 
Labelling of dietary foods is regulated by EU Directive 1999/21, which extends EU 
Directive 89/398 on foods for particular nutritional purposes. Health claims for these 
foods are subject to pre-market clearance. 
 
The legislation on claims in individual EU member states may be more extensive than 
the rules set out by the EU directives. Scrutiny of health claims may be performed 
either pre- or post-clearance of the food product. 
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The European Commission recently proposed to harmonise legislation on (EC, 
2001a): 
1) Nutritional claims. A draft list has been provided, featuring a number of 
permissible nutritional claims. 
2) Functional claims, i.e. health claims that relate to the positive effect of a nutrient 
on a bodily function. 
 
Netherlands 
 
Dutch legislation on nutritional claims follows EU Directive 90/496 and pertains only 
to the nutritional value of foodstuffs. 
 
In the Netherlands, a distinction is made between “health products” and medicinal 
products. “Health products” bear the shape of a pharmaceutical, such as tablets and 
tinctures, but they are distinguished from medicines by the attached claims that relate 
to health without making them medicines. It should be noted that food supplements 
too fall under the Dutch definition of health products. Health claims for health 
products can be scrutinised voluntarily. For this scrutiny, three institutions have each 
developed their specific code of practice. These institutions are: 
1) Advertising Code Foundation (“Stichting Reclame Code”. 
http://www.reclamecode.nl/SRC.asp) in which the media and consumers 
participate 
2) Verification Council (“Keuringsraad”, http://www.koagkag.nl) in which branch 
organisations (producers, media, marketeers, drug retailers) participate. 
3) Nutrition Centre (“Voedingscentrum”, http://www.voedingscentrum.nl), which 
is independent and disseminates public information on nutrition and food safety. 
In all three procedures, relevant scientific data must support the proposed health 
claim. 
 
A Code of Practice has been developed by the Nutrition Centre, which specifies the 
criteria that should be fulfilled by the scientific evidence in support of a claimed 
health benefit of food and drink products. Adherence to the Code is on a voluntary 
base (Nutrition Centre, 1998). 
 
Criteria for the advertisement of “health products”, i.e. products with either a 
pharmaceutical appearance or attributed health-function, have been formulated by the 
Verification Council (KOAG/KAG, 2000a). One important criteria in the Verification 
Council’s evaluations is that no pharmaceutical- like properties may be ascribed to the 
health product. 
 
Complaints about these advertisements can be assessed by the Advertising Code 
Committee, which verifies their compliance with the Dutch Advertising Code 
(Advertising Code Committee, 2000). Previous evaluations by the Verification 
Council of health claims submitted to the Advertising Code Committee will be taken 
into account. 
 
Claims pertaining to vitamin preparations, as a category of food supplements, are 
specifically regulated by the Commodity Act Rule waiving Vitamin Preparations 
(“Warenwetregeling Vrijstelling Vitaminepreparaten”). These claims have to be 
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supported by scientific evidence, that the manufacturer or trader must be able to 
deliver at request (Vroom Cramer, 1998). 
 
In addition, fortification of products with micro-nutrients and the claims pertaining to 
fortified products are regulated. Fortification is allowed if its purpose is to compensate 
for micro-nutrient losses during processing or to create a substitute for another 
product containing the micronutrient, i.e. vitamin-fortified margarine vs. milk butter. 
Several micro-nutrients are prohibited (e.g. iodine) or allowed only in small amounts 
(e.g. vitamins A-D) due to their narrow safety margins (Vroom Cramer, 1998). 
 
Sponsorship of non-profit health associations provides for an additional opportunity to 
attract consumers’ attention to health-promoting food products. The Dutch Heart 
Foundation (http://www.hartstichting.nl) allows companies to display the 
foundation’s logo on food products exclusively for fund-raising acitivities. Several 
conditions must be fulfilled, however, to obtain permission to use the logo. The food 
product in question should i) be a food of preference for the Nutrition Centre, or ii) 
bear a heart-related health claim that has been positively evaluated according to the 
Nutrition Centre’s Code of Practice. In addition, the manufacturing company’s image 
should be positive and compatible with a healthy lifestyle (no tobacco companies 
allowed, for example). The logo should be displayed such that its conjunction with 
fund-raising is obvious to the consumer and that it’s not mistaken for a quality mark. 
As example, Unilever’s phytosterol-enriched margarine spread Becel Pro Activ was 
allowed to bear the Heart Foundation’s logo during several months while the 
foundation was receiving royalties from the sales of Becel Pro Activ. 
 
In a similar vein, the Dutch Digestive Diseases Foundation (http://www.mlds.nl) 
offers sponsoring companies the opportunity to seal certain food products with the 
foundation’s logo against a fixed fee under the following terms: 
?? The product should be compatible with the foundation’s message; for example, 
it should be high in fibre and/or moisture. 
?? Claims should be scientifically supported. 
?? The foundation logo symbolises the company’s support for the foundation and 
should not be mistaken for a quality mark. 
 
USA 
 
In the United States, a distinction is made for permissible health claims on foods and 
on food supplements. Please note that the American definition of a health claim is 
narrower than ours and limits itself to “substance-disease” claims. 
 
Three types of claims are discerned for both foods and food supplements (FDA, 
2001c): 
1) “Substance-disease” claims, which are also referred to as “health claims” in the 
USA. These claims pertain to the beneficial effect of a food substance on human 
health without becoming medicinal (i.e. to cure, mitigate, or diagnose disease). 
A limited number of acknowledged health claims are permitted on foods, such 
as prevention of cancer by fruit consumption (Kurtzweil, 1998). Fewer 
acknowledged health claims are allowed on food supplements than on foods. 
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Novel substance-disease claims can be cleared for labelling through three 
regulatory pathways: 
?? Claims may be submitted to the FDA, which will evaluate the scientific 
background supporting these claims. The FDA requires that “significant 
scientific agreement” exists for such claims to be cleared (FDA, 2001c). 
?? Claims on foods (not on dietary supplements) may be based on authoritative 
statements from scientific bodies, such as the National Academy of Sciences 
(NAS) and federal institutions such as the National Institutes of Health. 
These claims should reflect consensus within these scientific bodies and be 
based on review of the scientific evidence. The following approved claim, for 
example, was based on a statement by NAS: "Diets rich in whole grain foods 
and other plant foods and low in total fat, saturated fat, and cholesterol, may 
help reduce the risk of heart disease and certain cancers" (FDA, 2001c). 
?? “Qualified” claims are allowed on food supplements (not on foods) as a 
result of a court decision on a recent lawsuit between a supplement 
manufacturer and the FDA (the “Pearson vs. Shalala” case). The FDA was 
required by the court to permit claims that did not match the FDA’s standards 
for “significant scientific agreement”, provided that qualifying language was 
used that would render these claims not misleading. The qualifying claims 
that have since then been approved by the FDA contain either qualifying 
remarks (rendering claims rather lengthy) or disclaimers (FDA, 2001c). 
 
2) “Nutrient content” claims on foods and food supplements (such as “high in 
calcium”), which pertain to the level of a nutrient for which a recommended 
daily intake or a daily reference value has been established. Such claims have to 
be submitted to the FDA for evaluation. In addition, nutrient-content claims 
may be based on authoritative statements, similar to substance-disease claims 
(FDA, 2001c). 
 
3) “Structure function” claims on foods and food supplements describing the 
relation between a nutrient and body structures, physiological functions, 
nutrition deficiencies, and common affections that are associated with “passages 
of life”. Claims related to severe diseases are, however, precluded. Structure-
function claims are not liable to the pre-market scrutiny and should be notified 
to the FDA within 30 days after market introduction. The burden of proof for 
these claims lies on the side of the FDA, which has to react to non permissible 
claims. A disclaimer should be added that, among others, the FDA has not 
evaluated the claim (FDA, 2001c). 
 
In addition, requirements for ingredient labelling of dietary supplements are less 
rigorous than for foods and allow for the omission of non-relevant ingredients and for 
the declaration of special nutrients (FDA, 1999). 
 
In addition to explicit health claims, several American producers of foodstuffs, food 
supplements, and pharmaceuticals are allowed to seal the logos of non-profit health 
organisations to their products and advertisements in return for sponsorship. An 
example is the labelling of Florida fruit products with health logos sponsored by the 
US State of Florida’s Department of Citrus (see 
http://www.ultimatecitrus.com/health.html). Florida orange juice labels are allowed to 
display logos of the American Cancer Society (reduced risk of cancer) and the March 
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of Dimes (reduced risk of birth defects), while Florida grapefruit is allowed to bear 
the American Heart Association’s logo (reduced risk of heart disease). It should be 
noted that the American Cancer Society will not accept new sponsors for this purpose. 
The American Heart Association, on the other hand, has a food certification program 
in place where food manufacturers can acquire permission to label their products with 
the “heart-check mark” (http://www.americanheart.org/FoodCertification/ ). Eligible 
food products must be low in fat, cholesterol, and salt, but contain enough nutrients. 
Fruit juices, fortified beverages, and lean beef are among the food products that have 
thus been approved. Logos of other American non-profit health organisations not 
mentioned here have also been linked to products and advertisements. 
 
It should be borne in mind, though, that American consumer laws and Federal Trade 
Commission standards apply to the use of logos as described above. Both the logo-
providing non-profit health organisation and the sponsoring food manufacturer have 
the responsibility to ensure that the logo display will not mislead the consumer. If, for 
example, the health organisation and the manufacturer have entered an exclusive 
agreement, this should be stated clearly. In addition, if the health organisation does 
not specifically endorse a labelled product, this should be stated too (OAG, 1999). 
 
3.4. Feed uses 
 
3.4.1. Feed and feed ingredients 
 
EU 
 
A list of materials, including plant products, that are allowed to be marketed as 
ingredients of compound animal feeds in the EU, is provided within EU Directive 
91/357. Additional clearance under EU Directive 90/220 is required for animal feeds 
and feed ingredients derived from field-tested and commercially released genetically 
modified crops, as long as the crop is considered a viable organism (see above). A 
specific EU Novel Feed Regulation, however, is anticipated to replace the animal feed 
evaluation under 90/220 in the EU in 2001. Contrary to the 90/220 directive, this 
novel regulation also covers the use of non viable GM products and requires post 
market monitoring and tracing methods for the novel feed. 
 
Netherlands 
 
Same as the EU for viable products (cultivation and/or import). For the import of non 
viable animal feed products , a voluntary notification can be made to the Dutch 
Ministry of Agriculture, Nature Management, and Fisheries. The outcome is not 
legally binding and does not apply to other EU Member States. 
 
USA 
 
American regulations on animal feed differ from their European counterparts. Feed 
ingredients that are allowed to be included in animal feeds are listed in the “Official 
Publication” of the Association of Animal Feed Control Officials (AAFCO), a 
voluntary organisation that advises authorities’ officials (http://www.aafco.org/). Each 
State of the USA may have its own feed regulations, additional to those of the Food 
and Drug Administration (FDA) (USDA, 2000). 
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“Nutraceuticals” as feed ingredients have apparently not been regulated yet, given the 
discussion inside AAFCO on whether or not nutraceuticals should be registered as 
feed ingredients and, consequently, evaluated for their safety (AAFCO, 1999). 
 
3.4.2. Feed additives 
 
EU 
 
Prior to market approval in the EU, new feed additives are evaluated for their safety 
and efficacy, i.e. animal performance and welfare . To this end, animal tests should be 
carried out (EU Directive 87/153; SCAN, 2000). 
 
Feed additives from genetically modified organisms that are similar to any on the 
market are not specifically regulated and are regarded as safe. The presence of 
transgenic DNA containing antibiotic resistance genes is, however, not allowed 
(SCAN, 2000). Proposals have been amended by the Europarliament to install 
mandatory labelling of feed additives that contain- or consist of- genetically modified 
organisms (EP, 2000b). This would imply that purified additives lacking transgenic 
components would not fall under this labelling requirement. 
 
USA 
 
Feed additives are considered animal medicines in the USA, hence they should be 
approved as a new animal medicine. The marketing of a feed additive that is generally 
recognised as safe (GRAS) by the FDA will, however, only require an expert’s 
opinion, eventually supported by literature data (USDA, 2000). 
 
3.4.3. Feed for special uses 
 
EU 
 
Feedingstuffs for particular nutritional purposes serve the nutrition of metabolically 
impaired animals. These feedingstuffs may consist of feed additives and should be 
distinguishable from ordinary feedingstuffs and medicated feeds. A number of 
applications for these feedingstuffs are permitted, including “reduction of acute 
intestinal absorptive disorders”, under EU Directive 94/39. 
 
USA 
 
To our knowledge, no specific regulations exist for special dietary feeds in the USA. 
 
3.5. Medicinal uses 
 
3.5.1. Human medicines 
 
EU 
 
Approval for the production of medicines by genetically modified organisms can only 
be granted by a “centralised” EU procedure as described by EU Directive 2309/93. A 
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comprehensive dossier should support the application for a medicine derived from 
genetically modified organisms. Guidance for applicants on the content of dossiers is 
provided by the European Agency for the Evaluation of Medicinal Products (EMEA) 
(EC, 1997). 
 
Three types of data must be collected for the marketing application dossier: quality-, 
preclinical-, and clinical- data. 
 
Quality includes medicine composition and stability, while special requirements have 
been formulated for vegetable products. 
 
Preclinical data comprise in vitro data, such as mutagenicity, and animal test data, 
such as pharmacokinetics and toxicity; the latter includes single dose- and repeated 
dose- tests, teratogenicity, and carcinogenicity. Specific guidance is provided for the 
pre-clinical testing of biotechnology-derived medicines (CPMP, 1997). 
 
Clinical trials are human trials in which pharmacokinetics, efficacy and toxicity are 
assessed. The order in which data are collected is not random, i.e. clinical trials are 
only permitted after safety and efficacy in animals have been assessed by preclinical 
trials.  
 
Human medicinal products are classified into two categories by EU Directive 92/26: 
1. Prescription medicines, which can only be sold through pharmacies. 
2. Non prescription (“over the counter”, OTC) medicines, i.e. medicines that can 
be obtained with- or without- a physician’s prescription (EU Directive 92/26). 
Several criteria are considered before a medicine is granted the OTC status, 
including the safety of the medicine, the ability of the patient to self-diagnose 
and to self-medicate with little or no professional instructions. 
Advertising is only possible for OTC medicines, not for prescription medicines.  
 
After their market release, medicines should be monitored for side effects. The 
“market authorisation holder”, together with health professionals and government 
officials should report side effects to the Member States and EMEA. Serious adverse 
effects have to be reported within 15 days, whereas other side effects are reported 
periodically (PhVWP, 1999). No special additional requirements have been 
formulated for the monitoring of biotechnology-derived medicines. 
 
Netherlands 
 
Advertisements for OTC medicines are under scrutiny of the Verification Council 
(Keuringsraad KOAG/KAG) in the Netherlands (KOAG/KAG, 2000b). The Dutch 
Medicine Evaluation Bureau recently advised the Dutch Minister of Health Welfare 
and Sports to allow the general sales (i.e. outside pharmacies and drug stores) of 
certain OTC medicines, such as vitamins and minerals (CBG, 2000a). 
 
In the Netherlands, pharmacovigilance is carried out by health professionals, medical 
specialist organisations, the marketing authorisation holder, and official bodies. For 
human medicines, these official bodies are the Medicine Evaluation Bureau and the 
Health Inspectorate (CBG, 2000b). 
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USA 
 
Under American legislation, the same stages in medicine testing prior to marketing 
can be discerned as in EU legislation (see above): quality, pre-clinical, and clinical. 
 
In the clinical stage, the medicine is tested as an “investigational new drug (IND)”. 
All relevant details of the preclinical tests and the IND-tests should be submitted in 
the “new drug application (NDA)”. If the NDA is approved by the reviewers, the new 
medicine is allowed to be marketed. 
 
A short-cut route can be followed if the medicine for which a marketing approval is 
sought is a “generic drug”, i.e. a medicine that has already been approved and that 
lacks patent protection. This route is named “abbreviated new drug application 
(ANDA)”. Apparently, USA legislation does not exempt biotechnology-derived 
medicines from this possibility, unlike EU legislation. For an ANDA, the “innovator” 
medicine should be proven to be bio-equivalent to the approved medicine, i.e. it 
should display the same uptake from the dosage (FDA, 2000d). Bio-equivalence 
studies should involve 24-36 human volunteers, in which the bloodstream uptake of 
the medicine is measured. These studies can substitute for preclinical- and IND- 
studies. ANDAs for “biologics” (e.g. proteins), however, are still a matter of 
discussion in the USA, as reported recently (Dove, 2001). 
 
Similar to the EU, the FDA discerns “prescription (Rx)” medicines and “over the 
counter (OTC)” medicines. OTC medicines are not classified into active compounds 
but into their indication or purpose. At present, “OTC drug monographs” are 
compiled, which stipulate composition and quality of approved OTC medicines 
(FDA, 2000e). If a new medicine’s composition concurs with that described in an 
OTC monograph, a simplified OTC medicine application can be filed instead of an 
NDA. 
 
Botanical products that have been marketed as food or food supplements and that are 
“generally recognised as safe (GRAS)” by the FDA (see section 3.3.1) can also be 
sold in the USA as OTC medicines (FDA, 2000f). 
 
Similar to the EU, pharmaceuticals must be monitored post-market for adverse 
effects. The FDA has programs in place for reporting adverse reactions, viz. the 
Adverse Event Reporting System (http://www.fda.gov/cder/aers/default.htm) for 
manufacturers, packers and distributors, and MEDWATCH for health professionals 
(http://www.fda.gov/medwatch). 
 
International harmonisation 
 
Regulatory authorities of the EU, USA, and Japan have joined forces in the 
International Conference on Harmonisation (ICH) to harmonise the requirements for 
medicine applications. The ultimate goal is the mutual acceptance of medicine 
application data that have been compiled in accordance with ICH guidelines (Nutley, 
2000). Consensus has already been reached on requirements for preclinical (S6 of 
[ICH, 2001]) and clinical data. Moreover, ICH guidelines have been prepared for the 
production of biotechnological medicines from genetically modified cell cultures (Q5 
& Q6 of [ICH, 2001]) 
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3.5.2. Veterinary medicines 
 
EU 
 
The requirements for dossier data for the registration of veterinary pharmaceuticals 
are quite similar to those for human pharmaceuticals (see section 3.5.1) (EC, 1997). 
Human toxicity is also relevant to veterinary medicines with regard to consumer 
safety. It should be noted that for veterinary medicines a maximum residue limit in 
food animals must be defined according to EU Regulation 2377/90. In addition, a 
withdrawal period has to be determined during which the medicinal product should 
not be administered to food animals prior to slaughter.  
 
Similar to human medicines, veterinary medicines can be either “prescription” or 
“OTC”, as EU Directive 90/676 defines which medicines can only be administered on 
prescription. OTC status of veterinary medicines has not been harmonised, though, in 
the EU. 
 
Netherlands 
 
Veterinary medicines that can only be dispended through the pharmacist  or the 
veterinarian  have been defined by the “canalisation” rules under the Dutch Law on 
Veterinary Medicines. After the market release of veterinary medicines, adverse 
reactions should be reported to the Centre for Veterinary Pharmacovigilance. 
 
USA 
 
The American legislation on veterinary pharmaceuticals by and large resembles that 
of human pharmaceuticals. Hence American legislation discerns “investigational new 
animal drugs (INADs)”, “new animal drugs (NADs)”, and “abbreviated new animal 
drug applications (ANADAs)” (FDA, 2000g). Guidance documents on the various 
issues surrounding veterinary medicines, i.e. specific uses and clinical testing, have 
been published by the FDA’s Center for Veterinary Medicine (FDA, 2000h).  
 
Similar to the EU, a distinction is made between prescription (“Rx”)- and OTC 
veterinary medicines. A veterinary medicine may be changed, however, from 
prescription- to OTC- status if long-term experience warrants its safe use (FDA, 
2000i). 
 
Once a medicine has been approved for commercial release, post-market reporting to 
the FDA’s Center for Veterinary Medicine of adverse reactions of veterinary 
medicines is mandatory for medicine manufacturers and voluntary for animal owners 
and veterinarians (FDA, 1998). 
 
International harmonisation 
 
Similar to ICH for human medicines, the International Cooperation on Harmonisation 
of Technical Requirements for Registration of Veterinary Products (VICH) seeks to 
establish mutual recognition of veterinary medicine dossiers between the EU, USA, 
and Japan. Guidelines have already been implemented for quality requirements of 
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veterinary medicines, while draft guidelines have been prepared for clinical trials, 
antihelminthics, and pharmacovigilance (VICH, 2001). 
 
3.5.3. Health economics 
 
One aspect that is currently receiving much attention of professionals involved in the 
human medicine approval process is that of health economics, also known as 
pharmacoeconomics. Pharmacoeconomic studies on pharmaceuticals take various 
economic and social aspects of the novel medicine into account, such as its cost 
effectiveness and its effect on the “quality of life”. Cost effectiveness include the 
pricing of the medicine compared to other medicines, but also savings made in other 
sections of healthcare, such as hospitalisation of patients, by use of the novel 
medicine. Cost-effectiveness considerations are nowadays pivotal for a medicine to 
get incorporated, for example, into reimbursement schemes of health insurance 
providers.  
 
EU 
 
There is no common EU guidance on the issue of pharmacoeconomics that we are 
currently aware of. A recent French study reviews pharmacoeconomic guidelines of, 
among others, EU member states and the USA (Baron, 2000). 
 
Netherlands 
 
Guidelines have been issued for pharmacoeconomic data to be supplied with the 
medicine application in The Netherlands (CVZ, 2000a; Riteco et al., 1999). 
 
It may be worth noting that dietary preparations are reimbursed by Dutch healthcare 
insurance companies under certain conditions, e.g. if they alleviate severe diseases, 
such as cow’s milk allergy in children till 2-3 years of age. The Dutch organisation for 
healthcare insurance companies is currently reviewing this policy of reimbursing 
dietary preparations. 
 
USA 
 
In the USA, pharmacoeconomic data provided by medicine companies to committees 
and other bodies that decide on eligibility of the medicine for therapy or 
reimbursement are considered “promotional” data. The quality of these data should 
fulfil the requirements formulated in Section 114(a) of the FDA Modernization Act of 
1997 amending Section 502(a) of the Food, Drug & Cosmetics Act. 
 
It may be interesting to note here that pharmacoeconomic studies show that specific 
diets can alleviate medical costs, as projected recently for American diabetes patients 
receiving special diets under “medical nutrition therapy” (Sheils et al., 1999). It has 
therefore been argued that special diets should be eligible for reimbursement under 
healthcare insurance programs.  
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3.6. Production Chain (GMP and similar conditions) 
 
3.6.1. Foods and food ingredients 
 
Chemical and microbiological contamination of foods should be prevented to avoid 
illness of the consumers. Current food hygienic standards are nowadays implemented 
by food industries in the frame of Good Manufacturing Practice (GMP) and Hazard 
Analysis at Critical Control Points (HACCP). The Codex Alimentarius Commission 
of the FAO / WHO has adopted such standards (Codex, 1997).  
 
The hygienic practices described by Codex involve, among others, the use and design 
of apparatus and machines that allow for cleaning, the prevention of contamination by 
personnel and training of personnel. For HACCP, a flow diagram of the food 
manufacture process is made. Critical control points (CCPs), i.e. essential points in 
the food production chain where samples can be drawn and possible contamination 
can be controlled, are then assigned in this process. Records are stored of data 
sampled at the CCPs, and instructions for control measures should be available in case 
a contamination is noted. 
 
EU 
 
EU Directive 93/43 stipulates the hygiene rules that food businesses should comply 
with in general, such as HACCP as described by the FAO/WHO Codex Alimentarius. 
A recent proposal of the European Commission for an EU General Food Regulation 
will also incorporate hygienic standards such as HACCP. This proposal will probably 
be implemented by the year 2002. 
 
Netherlands 
 
HACCP is mandatory for the Dutch food industries under the Dutch Commodity Act 
Rule on the Hygiene of Foodstuffs (“Warenwetregeling Hygiëne van 
Levensmiddelen”), implementing EU Directive 93/43. 
 
USA 
 
GMP is mandatory for the American food industry (Code of Federal Regulations, 
Title 21, Part 110). In addition, HACCP is mandatory too for a number of foods, 
including fruit- and vegetable- juices. Guidance on HACCP has been published by the 
FDA (FDA, 2000j). 
 
3.6.2. Food supplements 
 
Netherlands 
 
Food supplements fall under the scope of the Dutch Commodity Act (“Warenwet”) 
and HACCP is therefore required for their production. 
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USA 
 
GMP is mandatory for food supplements containing more than 30 mg iron per dosage 
(Code of Federal Regulations, Title 21, Part 110.50). 
 
A voluntary quality program for food supplements has been launched by the US 
Pharmacopeia. This program focuses on the accurate labelling of the composition of 
food supplements containing vitamins, minerals, and herbal extracts. Manufacturers 
complying with this program are allowed to display a US Pharmacopeia quality mark 
on their product labels (USP, 2000). 
 
International harmonisation 
 
Requirements for good manufacturing practices (GMP) are to be formulated in the 
near future in both EU and USA in the context of the EU-USA harmonisation of 
legislation on food supplements (TABD, 2000). 
 
3.6.3. Animal feeds 
 
EU 
 
EU Directive 95/69 establishes basic requirements under which manufacturers of 
commercial feedingstuffs should work, including the requirement to exclude 
contamination of animal feed by harmful organisms. 
 
Netherlands 
 
Most (>90%) of the Dutch animal feed producers have voluntarily adopted GMP 
conditions as established by the national Product Board for Animal Feed. These GMP 
conditions include the intake and production of feedingstuffs that comply with 
microbiological- and residue- criteria. Recently, it has been decided that GMP will be 
extended with HACCP to better adapt feed manufacture to food industry standards 
(PDV, 1999; PDV, 2001). 
 
USA 
 
In the US, the Association of Animal Feed Control Officials (AAFCO) provides 
guidance for implementation of FDA standards for Current Good Manufacturing 
Practice in animal feed manufacture. These standards include among others the 
cleaning of manufacturing apparatus, the quality control of raw materials and 
products, and safety during transport (AAFCO, 2000). 
 
3.6.4. Human and veterinary medicines 
 
EU 
 
In the European Union, good manufacturing practices of medicinal products for both 
human and veterinary use are quite similar and therefore will be treated together. 
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It is mandatory that the manufacturers of medicinal products comply with the 
guidelines for Good Manufacturing Practice. Such practice includes the establishment 
of a quality control department, the employment and education of qualified personnel, 
the use and decontamination of appropriate housing and equipment, the storage of 
records related to the manufacture processes, and the execution of manufacturing 
instructions, inspection, and monitoring. These requirements are further detailed in the 
Guide to Good Manufacturing Practice for Medicinal Products (EC, 1997). 
 
Several criteria that have been formulated in the abovementioned guide appear 
relevant to the production of pharmaceuticals in genetically modified plants: 
?? Storage of crude plants materials and the products manufactured from them. 
?? Processing instructions and quality control. 
?? Characteristics of the crude plants, including active components, contaminants 
and growth conditions of the crude plant (cultivation areas, separate harvested 
batches). Impurities that cannot be controlled should be assayed for their 
toxicity. 
 
Guidance for the determination of quality of crude plants are provided by the 
Guideline on Quality of Herbal Remedies (pp. 195-202, vol. 3A of [EC, 1997]) and 
EMEA’s Herbal Medicinal Products Working Party (HMPWP, 2000). The 
forthcoming European Pharmacopeia (fourth edition, to appear in summer 2001) will 
devote attention to these EU quality guidelines. 
 
The implementation by EU Member States of EU regulations on herbal medicinal 
products, including those on GMP, and the use of quality standards laid down in 
monographs (e.g. pharmacopeia) are reviewed in a recent study (AESGP, 1998). 
 
Specific guidelines exist for products manufactured with modern biotechnological 
techniques. In general, full information shall be supplied on any biotechnologically 
derived compound, including its manufacture and purity. The guidelines, however, 
restrict themselves to cultures of genetically modified cells (including plant cells) and 
transgenic animals (pp. 75-80, vol. 3A, and pp. 205-216, vol. 4 of [EC, 1997]). 
 
USA 
 
The requirements for the manufacture of medicines from plants are practically the 
same as in the EU (FDA, 2000f). 
 
3.7. Patentability of the new product 
 
Patents are exclusive rights to commercially exploit an invention. First, the invention 
should comply with the general conditions of patentability. This means, for example, 
that the invention should be non-obvious for a person who is skilled in the art, that it 
contributes to an improvement of present technology, that the invention can be carried 
out in practice, and that the description allows for reproducibility. Second, special 
patent rules apply to biological subjects and their constituents in the EU and the USA 
(Van de Graaf, 1997). 
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3.7.1. Patenting GM plants 
 
Several options are available to attain the exclusive rights to exploit genetically 
modified plants in the EU (Santaniello, 2000) and the USA (Evenson, 2000). 
Protection can be attained either for plant varieties (asexually- and sexually- 
reproducing) or plant materials that are not varieties (e.g. genes expressed in multiple 
plant -species or -varieties). 
 
EU 
 
In the EU, plant varieties cannot be patented as these are covered by plant breeder’s 
rights. This implies that all that does not fall under the definition of a plant variety are 
exempt from this restriction. Examples of plant products that thus can be patented are 
genes that are expressed in multiple varieties of unrelated plants, fruits that are not 
used for plant reproduction (such as apples), and non-stable crosses of plants. 
Although the European Patent Office does not fall under European legislation, the EU 
has promulgated EU Directive 98/44 on biotechnological inventions which has to be 
implemented in its member states (Santaniello, 2000; Van de Graaf, 1997). 
 
USA 
 
American “plant patents” cover the use of a single asexually reproducing plant variety 
and its progeny. Sexually reproduced plant varieties can be protected by plant 
breeder’s rights. Exclusive rights that do not protect plant varieties, are “trade secrets” 
and “utility patents” (Evenson, 2000). 
 
In the USA, parts of the manufacture procedure and resources (e.g. parent breeding 
lines, genetic transformation methods) can be protected as “trade secret”, i.e. 
infringement of confidentiality can be litigated (Evenson, 2000). 
 
No utility patents can be granted for nature and therefore only unnatural plants are 
eligible for patenting in the USA, like it has been the case for maize enriched with the 
essential amino acid tryptophane. As some genetically modified plants can be 
considered unnatural too, they may be submitted for a patent (Van de Graaf, 1997). 
 
The claims that are made in the patent define the applications for which the patent 
confers exclusive rights to the patent owner. The claims, however, should be “reduced 
to practice”, in other words: their practical feasibility should be demonstrated. The US 
Patent and Trademark Office recently issued revised guidelines to tighten the scrutiny 
on this aspect (Kowalski, 2000; Smaglik, 2000). 
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4. Biosafety Considerations of Transgenic Crops Producing 
Functional Foods, Nutraceuticals and Pharmaceuticals 
 
4.1. Case-by-case 
 
Above, we distinguished between production of pharmaceuticals, functional foods, or 
nutraceuticals in crops, and crops to be used entirely (raw or processed) for oral 
administration of the relevant compounds. Concerning recombinant production, the 
specific characteristics of the crop and the recombinant compounds, the culture 
requirements, and the (national and international) guidelines and regulations make 
each production system an individual case. Biosafety assessments therefore needs to 
be approached on a 'case-by-case' basis. This will be the starting point.  
 
4.2. Crop type  
 
Any crop type, i.e. any food, feed and industrial crop, has the potential to be 
genetically modified to produce pharmaceuticals or nutraceuticals. Relevant 
considerations before choosing a specific crop for transgenic medical or health 
purposes is the familiarity with the agronomic characteristics of the crop, specific 
methods of crop protection, weed/pest management and possibilities for the removal 
of agrochemical residues. Major attention should be given to the required containment 
conditions and the biological containment characteristics of the crop. The biological 
characteristics of the plant in the field, such as dispersal of pollen, seeds and other 
diaspores, and its hibernation capacity or the invasiveness are relevant in this respect. 
Outcrossing to adjacent fields with the same crop cultured for traditional purposes 
must be prevented. The same holds for outcrossing to wild or weedy crossable 
relatives. Also possible new effects, due to the presence and characteristics in the 
plant of the specific health compound, to organisms that accidentally feed on it or live 
in its phyllosphere or rhizosphere should be considered. Several production systems, 
especially in the case of pharmaceutical production, will require defined greenhouse 
facilities. Chapter 5 focuses on the requirements for greenhouses to be used for the 
culture of crops aiming at the production of pharmaceuticals and nutraceuticals.  
 
4.3. Transgene and transgene product  
 
The type of the functional food, nutraceutical, or pharmaceutical in the plant and its 
aim needs to be considered. In the case of pharmaceuticals it may be an antibiotic, a 
hormone, an enzyme, a vaccine or an immunological protein. Active components in 
functional food crops can involve flavanoids, carotenoids, multiple-unsaturated fatty 
acids, oligosaccharides, fibres but also increased mineral contents and vitamin level. 
Each type of compound, when present in unnatural quantities, or in a new host plant, 
may require its own safety approach. 
 
In the same vein, the “transgene-centred approach to biosafety” described in scientific 
literature may serve as an auxiliary tool for the biosafety assessment of genetically 
modified plants (Metz & Nap, 1997; Gilissen et al. 1998). This approach enables to 
answer concrete questions about ecological and toxicological consequences of the 
presence of gene xxx or gene product XXX and their metabolites in a genetically 
modified plant.   
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4.4. Handling during culture and harvest  
 
Attention should also be given to the safety of the farmers. Different requirements for 
handling during culture and harvest may be needed for a crop in its new destination as 
a medicinal plant or functional food crop.  
 
4.5. Residues  
 
Each crop produces residues that can play a role in further food chains, as feed, or as 
manure. The presence and the concentration of a (new) medical or health compound 
in these residues should be analysed, and its possible effects should be considered. In 
the case of residues from a food crop used for the production of a pharmaceutical, it 
might be used for further purposes e.g. as feed or as green manure. In such case, the 
pharmaceutical should be removed or inactivated completely. 
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5. Blueprint of a Greenhouse  
 
5.1. General 
 
The demands put on a greenhouse suited for culturing genetically modified plants for 
the production of nutraceuticals, functional foods and pharmaceuticals depend on both 
the legislation related to the GMO status of the produced plants and on specific 
production requirements claimed by the company that processes the harvested 
transgenic plant material. For many manufacturing processes these production 
requirements are laid down in EU Directives describing principles and guidelines of 
“good manufacturing practices” (GMP). Unfortunately, no GMP directives exist about 
premises and equipment for transgenic plants that produce pharmaceuticals or 
nutraceuticals. Production of pharmaceuticals involves legislation related to medicines 
(see EMEA website: http://www.eudra.org/emea.html). Production of nutraceuticals 
involves legislation related to foods, including novel food (Regulation 258/97). 
Currently, the EMEA (The European Agency for the Evaluation of Medicinal 
Products) Working Party on Herbal Medicinal Products agreed to a proposal for 
guidance on good agricultural and collection practice in relation to the GMP guide for 
Active Pharmaceutical Ingredients (pp. 95-101 of [HMPWG, 1999]). This document 
is the only one available that describes cultivation of plants that are used for medicine 
production and can also be used to outline Good Agricultural Practice (GAP) for both 
pharmaceutical and nutraceutical production. The GAP guidelines apply to the 
production of all plant materials used in the food, feed, medicinal, flavoring and 
perfume industries. It applies to all methods of production including organic 
production in accordance with the European regulations. Producers, traders and 
processors of medicinal and aromatic plants should comply with the GAP guidelines, 
document this, by a Way Bill (batch documentation) and demand that their partners 
also meet these requirements. 
 
5.2. Legislation for production in greenhouses 
 
5.2.1. Legislation in the EU 
 
Combination of the requirements laid down in the GAP guidelines and to the 
Directives related to the transgenic status of the plant can be used to outline the 
conditions under which genetically modified plants can be grown in greenhouses for 
medicinal production. The latter, however, poses a problem: no directives are made 
that deal with the production of transgenic plants in greenhouses. EU Directive 90/220 
is about the deliberate release into the environment of genetically modified organisms 
and was recently amended by EU Directive 2001/18, which has to be implemented in 
Member State legislation in 2002. EU Directive 90/219 is about the contained use of 
genetically modified micro-organisms. Production of pharmaceuticals or 
nutraceuticals in greenhouses is not about deliberate release in the environment. In 
contrast, it can have a high level of containment (especially under GAP conditions). 
On the other hand, contained use of micro-organisms (directive 90/219) involves 
techniques and risks that are very different from contained growth of genetically 
modified plants. To fill up this gap in legislation, EU member states have made 
legislation based on EU Directives 90/219 and 90/220 for the production of 
genetically modified plants. EU Directive 90/220 consists of four parts. The first part 
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contains the general provisions: member states must take appropriate measures to 
avoid adverse effects on human health and the environment which may arise from 
deliberate release of GMOs in the environment. The second part contains the 
provisions for the deliberate release of GMOs into the environment for research and 
development purposes. The third part contains provisions for market release of GMO-
derived products and the fourth part contains additional procedural considerations. 
Further information is provided by Kok et al. (1996). In this study also differences 
related to implementation of Directive 90/220/EEC into national law are provided. 
Several differences exist in the application procedures in the different member states 
(administrative procedures, requirements for field trials, requested information for the 
technical dossier, necessary measures in field trials related to differences in agro-
ecological environment, safety requirement for field trials).  
 
5.2.2. Legislation in the USA 
 
Legislation in relation to production facilities in the USA is essentially comparable to 
that in Europe. 
 
5.2.3. Legislation in The Netherlands 
 
In The Netherlands, the COGEM (commission on genetic modification) deals with 
applications for use of genetically modified organisms. The COGEM evaluates 
applications via a case by case scenario. The criteria that are used are given in the 
“Rule on genetically modified organisms and the pertinent COGEM guidelines” 
(http://www.minvrom.nl/minvrom/pagina.html?id=1&goto=1489; published June 
1998). COGEM describes the conditions for greenhouses, climate rooms etc. for 
production of transgenic plants. The greenhouse facilities needed for transgenic plants 
that produce pharmaceuticals or nutraceuticals are similar. First, the implications of 
the GAP guidelines for genetically modified plant production will be discussed. For 
this, the text in this guideline will be discussed in relation to specific demands on the 
greenhouse facilities and demands for plant production. Hereafter, the greenhouse 
facilities related to the transgenic status of the plants will be discussed. For this, EU 
directive 90/219/EEC and 90/220/EEC in combination with the Dutch rules on 
genetically modified organisms of the COGEM will be discussed. Finally, the 
information of the GAP guidelines and of the directives related to genetically 
modified organisms will be combined to set-up a blueprint for a greenhouse for the 
production of pharmaceuticals and nutraceuticals and functional foods.  
 
5.3. Greenhouse requirements and GAP 
 
The consequences of the principles and guidelines for GAP for greenhouse 
construction will be addressed in relation to the different phases of plant production 
and plant processing. 
Whilst the recommendations set out below should be considered to be generally 
applicable, individual products may present particular quality control issues. Thus, the 
production and control of each product must be given careful individual consideration 
taking fully into account any special features. 
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5.3.1. Seeds and propagation material  
 
The occurrence of not species/variety- identical plants and parts of plants has to be 
controlled in the course of the entire production process. This can easily be performed 
in greenhouses (better than in the field). No special demands have to be made 
regarding greenhouse constructions. 
 
5.3.2. Cultivation 
 
Depending on the mode of cultivation of transgenic plants for production of 
nutraceuticals or pharmaceuticals, growers should follow certain Standard Operating 
Procedures for cultivation. These are not described in any guidelines or directives but 
have to be elaborated by the growers themselves. In general, care should be taken to 
avoid environmental disturbances. Greenhouses can be designed in such a way that 
the probability for such disturbances is at an acceptable level. For instance, the use of 
gauze in front of windows and the connection of the entrance of the greenhouse 
compartments to a corridor (atrium) which can only be entered via an air- lock ensures 
that no insects can enter and that no pollen can exit the greenhouse.  
 
Care has to be taken that no sludge, soil contaminated with heavy metals, residues of 
plant protection products or any other not naturally occurring chemicals can enter the 
greenhouse. Irrigation water should be as free as possible from contaminants, such as 
faeces, heavy metals, pesticides, herbicides and toxicologically hazardous substances. 
Pesticide and herbicide application should be avoided as far as possible. The use of 
pesticides has to be documented. It is obligatory that the buyer of the batch be 
informed of the brand, quality and date of pesticide use in a written form.  
In greenhouses the use of soil type, fertilizers and pesticides can easily be optimized 
(especially compared to transgenic plants that grow in the field). In fact, nowadays in 
the case of regular crop production in greenhouses these demands are already met.  
 
5.3.3. Harvest 
 
In the course of the harvest, care should be taken to ensure that no toxic weeds can 
mix with the harvested crop. Damaged and perished plant parts must be promptly 
eliminated. The harvested crop must be protected from pests, mice/rodents and 
domestic animals. Pest control measures should be documented. 
All these requirements have no extra effects on the demands on greenhouses facilities. 
 
5.3.4. Primary processing 
 
Primary processing includes steps of processing such as washing, freezing, distilling, 
drying etc.. All these processes must conform to European and national regulations. 
Depending on the production process, primary processing (such as drying) may take 
place in special compartments of the greenhouse. In many cases specialized 
companies will conduct primary processing. Requirements for the location for 
primary processing are comparable to those mentioned under “cultivation”.   
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5.3.5. Packaging 
 
The harvested product should be promptly packaged according to the demands of the 
pharmaceutical company that processes the plant material. This can be performed in 
special compartments of the greenhouse. 
 
5.3.6. Storage and transport  
 
Storage and transport should be according to the demands of the pharmaceutical 
company that processes the plant material. This can be performed in special 
compartments of the greenhouse. 
 
5.3.7. Equipment 
 
Equipment should be easy to clean in order to eliminate the risk of contamination. All 
machinery (preferably non-wooden) should be mounted in an easily accessible way 
and must be well serviced and regularly cleaned. Fertilizer and pesticide application 
machinery must be regularly calibrated. 
 
5.3.8. Personnel and facilities 
 
Personnel should receive adequate education before performing tasks that require this 
knowledge. All processing procedures should fully conform with both EU guidelines 
on food hygiene (among others EU Directive 93/43) and the general principles for 
food hygiene of Codex Alimentarius as well as EU Directive 91/356 on good 
manufacturing practice for pharmaceuticals. 
Personnel should be required to have a high degree of personal hygiene (toilets must 
have hand washing facilities etc.). Persons suffering from known infectious diseases 
transmittable via food, including diarrhoea, or being transmitters of such diseases, 
must be suspended from areas where plant processing takes place or wear appropriate 
protecting clothing, until their complete recuperation. Finally, the welfare of all staff 
involved in growing and processing shall be ensured. 
 
So, in conclusion, the greenhouses must have proper washing facilities and care has to 
be taken that the personnel is well educated and does not work when suffering from 
infectious diseases. 
 
5.3.9. Documentation 
 
The following items must be documented: 
?? All starting materials and processing steps have to be documented including the 
location of cultivation. Field records showing previous cropping and inputs should 
be maintained by all growers.  
?? All batches from coherent areas should be unambiguously and unmistakably 
labelled (e.g. by the application of a batch number).  
?? Batches from differing areas shall be mixed only if it is guaranteed that the 
mixture in itself will be homogenous. Such mixing procedures should also be 
documented. 
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?? It is essential to document the type, quantity and the date of harvest of the crop, as 
well as the chemicals and other substances (e.g. fertilizers, pesticides and 
herbicides, growth regulators, etc.) used during crop production. 
?? The application of the fumigation agents such as phosphin must be entered into 
batch documentation. 
?? All processes and procedures that could bear an impact on the quality of the 
product must be entered into the batch documentation. 
?? All agreements (production guidelines, contracts, etc.) between producer and 
buyer should be fixed in a written form. It should be documented in a Way Bill 
(batch documentation) that cultivation, harvesting and production have been 
performed in accordance with the GAP Guideline. Minimum information included 
in the Way Bill should cover geographical definition of growth place, country of 
origin and responsible producer. 
?? The results of audits should be documented in an Audit Report (copies of all 
documents, Schlagkartei, Audit Reports, Analyse Reports) to be stored for a 
minimum of 1 0 years. 
?? Special circumstances during the growth period, which may influence the 
chemical composition like extreme weather conditions, pests - particularly in the 
harvest period - must be documented. An advantage of greenhouses is that the 
climate can be controlled.  
 
5.3.10. Education 
 
It is extremely advisable to educate all personnel dealing with the crop or those 
engaged in the direction of the production regarding production techniques and the 
appropriate use of herbicides and pesticides. 
 
5.3.11. Quality assurance 
 
Agreements between producers and buyers of medicinal and aromatic plants, with 
regard to quality questions, e.g. active principles and other characteristic ingredients, 
optical and sensoric properties, limit values of germ numbers, plant protection 
chemical residues and heavy metals, must be based on internationally recognized or 
national specifications and should be laid down in written form. 
 
5.4. Implementations of the Dutch regulations on greenhouse 
requirements 
  
Implementations of the Dutch regulations on genetically modified organisms on 
greenhouse requirements for production of pharmaceuticals and nutraceuticals and 
functional foods is based on Directive 90/219/EEC and 90/220/EEC. The purpose of 
physical containment is to prevent spreading of genetically modified organisms in the 
environment. For production of plants three types of greenhouses are described: PK-I 
(greenhouse [“plantenkas”] 1), PK-II and PK-III. PK-I and PK-II have facilities aimed 
to limit spreading of pollen, seeds and reproductive parts of genetically modified 
plants. In PK-I plants may grow in normal soil. PK-II plants need to grow on special 
substrates (e.g. soil in pots, rockwool). PK-III is suited for activities with normal 
plants or GMO-plants in combination with genetically modified micro-organisms. 
Plants that are genetically modified via micro-organisms, for instance Agrobacterium 
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tumefaciens, can only be produced in PK-I or PK-II after they are freed from the 
genetically modified micro-organsims. This has to be shown with a validated method 
(is often very difficult). 
 
The type of greenhouse (PK-I, PK-II or PK-III) that needs to be used also depends on 
the inserted gene, whether or not generative plant parts are covered (paper bags) and 
the plant type (are related plant species present in the environment?). COGEM gives 
detailed information  about the containment level needed for greenhouses for a 
particular GMO (appendix C pp 111-114 of the “regeling genetisch gemodificeerde 
organismen en richtlijnen van de cogem bij deze regeling”, juni 1998). 
 
Construction demands for the different types of greenhouses: 
 
5.4.1. PK-I greenhouse 
 
?? Greenhouse has permanent structure with walls and roof, especially made for 
growing of plants. 
?? Greenhouse must be entered via a door that can be locked. On this door a sign 
must be present indicating the GMO status of the plants. Also, the names and 
telephone numbers of at least one employee involved and of the biological safety 
functionary must be on the door. 
?? If plants that can spread via plant parts in the soil, plates must be inserted at least 
50 cm deep (or till groundwater level) to prevent spreading. 
?? If insect-proof gauze is used, the walls and the roof of the greenhouse are allowed 
to be a construction covered by the gauze. 
?? If an insect-proof greenhouse is used, the greenhouse needs to be entered via an 
atrium with a door that can be locked. In the atrium and greenhouse all ventilation 
canals need to be covered with insect-proof gauze. 
 
5.4.2. PK-II greenhouse 
 
?? Greenhouse has a permanent structure with walls, roof and floor especially made 
for growing of plants. 
?? Greenhouse must be entered via a door that can be locked. On this door a sign 
must be present indicating the GMOs status of the plants. Also, the names and 
telephone numbers of at least one employee involved and of the biological safety 
functionary must be on the door. 
?? The floor of the greenhouse is constructed in a way that plant parts can not spread 
via the soil. 
?? Ventilation facilities (in- and outlets) are covered with insect-proof gauze. 
?? If activities with genetically modified micro-organisms are carried out, a 
washbasin must be present. 
 
5.4.3. PK-III greenhouse 
 
?? Greenhouse has permanent structure with walls, roof and floor especially made for 
growing of plants. 
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?? The contained area is: the greenhouse, an air- lock and workrooms connected to 
the greenhouse where activities with genetically modified micro-organisms are 
carried out. 
?? The workroom is to be entered via an air- lock. The entrance door of the air-lock 
must have a lock. On the door the biohazard sign must be present and the names 
and telephone numbers of at least one employee involved and of the biological 
safety functionary. 
?? A contained dressing room with washbasin and soap dispenser must be present. 
Operation of the tap of the washbasin and the soap dispenser must be possible  
without using hands. 
?? The windows of the workroom are closed and sealed with kit. 
?? The floor has to be waterproof. A collection facility is present for waste water of 
greenhouse, workroom, atrium, washbasin and shower. If air release of this 
facility is outside the greenhouse, a HEPA filter must be present. 
?? Appropriate facilities are present for inactivation of genetically modified micro-
organisms. 
?? A ventilation system is present that ensure a air pressure that is 30 Pa lower in the 
greenhouse than the ambient air pressure. The air pressure in the workroom is 
lower than in the contained dressing room and shower; these have an air pressure 
lower than that of the clean dressing room (and outside air pressure). 
?? Possible additional demand: if the only passage between clean and contained 
dressing room is an air- lock, a shower must be built in the air-lock. 
?? Possible additional demand: An air- lock for outlet of materials. This air- lock must 
have two doors that can not be opened at the same time. 
 
5.5. Conclusions for greenhouse facilities  
 
Production of pharmaceuticals and nutraceuticals in GMOs in greenhouses is bound 
by special rules related to the transgenic status of the plants and according to the 
guidelines for GAP. GAP must be discussed with the company that processes the 
harvested transgenic plant material and certain Standard Operating Procedures for 
cultivation must be agreed upon. The GAP guidelines EMEA/HMPWG/25/99 can be 
used as a reference. As a result of GAP and GMO legislation, special demands need to 
be met with regard to the methods for plant production and to the required greenhouse 
facilities. The demands related to the greenhouse facilities are summarised in the 
Table 2. PK-I and PK-II conditions can easily be introduced in most greenhouses. 
GAP demands that extra rooms for primary processing, packaging and storage are 
made. This is probably possible at reasonable costs. However, PK-III conditions 
require substantial investments related to the extra rooms, waterproof floors, air- locks, 
ventilation system with lowered pressure etc.  
 
The type of greenhouse (PK-I, PK-II or PK-III) that needs to be used depends on the 
inserted gene, whether or not flowers are covered and the plant species. Careful 
selection of especially the plant species may overcome the need for PK-III facilities. 
COGEM gives detailed information about the containment level needed for 
greenhouses for different GMOs. 
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Table 2 Facilities related to different levels of containment. 
 
PK-I greenhouse PK-II greenhouse PK-III greenhouse 
Normal greenhouse, floor 
not necessary (see 
description) 
Normal greenhouse with 
floor 
Normal greenhouse with 
floor 
Insect gauze  Insect gauze  Airlock(s) for personnel 
Atrium for entrance of the 
greenhouse 
Atrium for entrance of the 
greenhouse 
Workroom(s) (closed rooms 
etc.) 
 Washbasin Dressing room 
  Washbasin + dispensers etc. 
  Waterproof floors 
  Collection facilities for 
waste water (HEPA filter) 
  Inactivation facilities for 
micro-organisms 
  Ventilation system that 
ensures lowered pressure 
(HEPA filter) 
  (Optional) airlock for 
personnel with shower 
  (Optional) airlock for outlet 
of material 
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6. Case: Crop Plants Producing rFSH 
 
6.1. Purposes 
 
A recombinant form of follicle stimulating hormone (rFSH) serves as model for a 
pharmaceutical protein produced by a hypothetical genetically modified crop plant. 
Follicle stimulating hormone (FSH) is a dimeric glycoprotein that induces ovulation. 
Together with luteinizing hormone it constitutes “gonadotropin”. Pharmaceutical 
preparations may contain either “chorionic gonadotropin” or “menopausal 
gonadotropin”. Chorionic gonadotropin is produced by trophoblast cells and is present 
in high amounts in serum and urine of females after 7-12 weeks of pregnancy. In 
addition, serum and urine of postmenopausal females contain elevated gonadotropins, 
which may serve as source of menopausal gonadotropin. FSH, LH, and gonadotropin 
have found application for infertility treatment in human females involved in in vitro 
fertilisation therapy, while in animals such as cows it is used as inducer of 
superovulation. In addition, some preparations are prescribed to treat male infertility 
as well, since FSH stimulates testosterone production. FSH cannot be applied within 
the crop as food or animal feed because FSH is orally inactive, which is most likely 
caused by intestinal degradation of FSH. Preparations containing FSH that have been 
approved for medicine use in the EU, The Netherlands, and USA are listed in Table 3 
(human) and Table 4 (veterinary). In most approved medicine applications, FSH is 
injected subcutaneously, intramuscularly, or intravenously.  
 
FSH for pharmaceutical purposes has been isolated from female body fluids and -
parts, such as urine, serum, and pituary glands. The advantages of FSH produced 
through recombinant DNA technology, however, are that i) the FSH preparation will 
be free of antagonistic luteinizing hormone activity (Prasmusinto, 1999) and ii) that 
pure FSH can be combined with other hormones in any desired ratio. The commercial 
recombinant FSH products are produced by genetically modified Chinese hamster 
ovary (CHO) cell lines. An additional advantage of the envisioned production of rFSH 
in crop plants rather than in CHO cells is the avoidance of the risk of transmission of 
mammalian pathogens (e.g. viruses, prions) through CHO cell culture, which 
eliminates the costs inherent to the efforts to control this risk under good 
manufacturing practices. 
 
An additional application for rFSH may be in pregnancy testing as reference material 
for in vitro diagnosis of human chorionic gonadotropin (hCG) or its subunits in 
female urine, plasma, or serum. Kits for hCG-diagnosis are available “over the 
counter” for clinical- and physician’s office- laboratories in the USA. To acquire 
marketing permission for such kits, the specificity and sensitivity of the test should be 
demonstrated in clinical trials (FDA, 2000k). 
 
In the EU, pregnancy tests fall under the definition of an in vitro diagnostic medical 
device and are thus regulated by EU Directive 98/79. For pregnancy tests, a 
distinction will be made between devices for self-testing (by users at home) or 
laboratory use. In the case of a self- testing device, a “notified body” (e.g. an 
independent certifying institution) must evaluate the technical data and the quality 
assurance program for production. Laboratory tests for pregnancy are exempt, 
however, from evaluation by a notified body. Both self- testing- and laboratory- 
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pregnancy tests should acquire a CE marking for compliance with European 
standards. 
 
6.2. Cultivation 
 
In The Netherlands, production conditions for a genetically modified crop can either 
be in-doors (“contained use”) or out-doors (“environmental release”) (see section 3.2. 
and chapter 5). The transgene product rFSH will possess endocrine activity, hence 
open-field cultivation of the novel crop may prove unfeasible unless its environmental 
hazard, e.g. for wildlife, can be negated. It may be worth noting here that FSH is 
orally inactive, hence consumption of the crop is unlikely to cause pharmacological 
effects. In the case of “contained use”, measures should be taken to avoid 
environmental escape of viable genetically modified plant material during handling of 
the harvested crop, else this will be regarded “environmental release”. The time-
savings and lesser dossier requirements for “contained use” should be waged against 
the lower costs of field cultivation, i.e. “environmental release”. 
 
6.3. Application for medicinal use 
 
FSH and rFSH have already been approved for use as human- and veterinary 
medicine (Tables 3 and 4). In the EU, full dossiers should be compiled for all 
biotechnology-derived medicinal products, including pre-clinical and clinical trial 
data, regardless if they may be “bio-equivalent” to previously approved products. Our 
hypothetical plant-derived rFSH preparation will therefore require full testing. A 
“short-cut” route for bio-equivalent biotechnology-derived “biologics” appears 
possible in the USA, but FDA’s policy on this issue is still evolving. In the most 
optimistic setting, less extensive testing will be required for the hypothetical “bio-
equivalent” rFSH in the USA than in the EU. 
 
rFSH has so far been produced by genetically modified cultures of Chinese hamster 
ovary (CHO) cells. The fact that FSH is a glycoprotein may complicate the 
demonstration of “bio-equivalence”, as glycosylation in plants may differ from that in, 
for example, hamster cells. 
 
It may be worth mentioning here that the difference in chemical composition between 
a “bio-equivalent” urinary gonadotropin and a reference medicine already approved 
for medicinal use has been disputed over in a lawsuit between two pharmaceutical 
companies in the USA. The court finally ruled in favour of the “bio equivalent” 
gonadotropin (US Court of Appeals, 1998; Biospace, 2000; PR Newswire, 2000). The 
disputed difference in protein glycosylation between the FSH molecules was 
described as “microheterogeneity”. The heterogeneity between crop-plant-derived 
rFSH and CHO-cell-derived rFSH may, however, be larger than the 
microheterogeneity observed between the urinary FSH molecules. It remains therefore 
uncertain if this lawsuit has set a precedent for our hypothetical rFSH preparation, if 
this were to be clinically equivalent to the currently approved CHO-cell-derived rFSH 
preparations. 
 
To avoid conflict with the protection afforded by patents and exclusivity terms to 
some FSH preparations already in the market (Tables 3 and 4), care should be taken in 
choosing the appropriate formulation and uses of the hypothetical rFSH. 
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With regard to the choice of production conditions, some reference is provided by an 
EU guideline on the manufacturing through genetically modified cell lines of 
cytokines, which are comparable to FSH in that they are physiologically active 
glycoproteins (pp. 223-235, vol. 3A of [EC, 1997]). It is recommended herein to pay 
attention to the post-translational modification of the cytokines under the 
manufacturing conditions, and to avoid contamination with viruses and DNA. Each 
batch should also be tested for activity in animals. 
 
Table 3 Recombinant FSH and gonadotropin approved for medicinal use 
 
Active ingredient  1 Brand name Manufacturer Region 2 
Follicle stimulating hormone, 
recombinant (follitropin-alpha) 
Gonal-F Serono EU, NL, USA 
Follicle stimulating hormone, 
recombinant (follitropin-beta) 
Puregon Organon EU, NL 
Follicle stimulating hormone, 
recombinant (follitropin-beta) 
Follistim Organon USA 
Gonadotropin, chorionic, 
recombinant human 
Ovidrel Serono EU, USA 
 
1  Gonadotropin contains both follicle stimulating hormone (FSH)- and 
luteinising hormone (LH)- activities. 
2  Data from BRD (2001), CVZ (2000b), EC (2000b), EMEA (2001) and FDA 
(2001d, 2001e). 
 
 
Table 4 Approvals for the use of non recombinant FSH and gonadotropin 
as human and veterinary medicine  
 
Active ingredient  1 Target species Region 2 
Follicle stimulating hormone human USA, NL 
Follicle stimulating hormone  3 all food producing animals EU 
Follicle stimulating hormone cow NL 
Follicle stimulating hormone cow, dog, mare, sheep, swine USA 
Gonadotropin human USA, NL 
Gonadotropin all food producing animals EU 
Gonadotropin cow, dog, goat, horse, rabbit, sheep, swine NL 
Gonadotropin cow, fish, swine USA 
 
1  Gonadotropin contains both follicle stimulating hormone (FSH)- and 
luteinising hormone (LH)- activities. 
2  Data from BRD (2001), CVZ (2000b), EC (2000b), EMEA (2001) and FDA 
(2001d, 2001e). 
3  Synthetic analogues (i.e. recombinant FSH) included 
 
Exploitation and regulation of plants genetically modified to express nutraceuticals and 
pharmaceuticals  
http://www.rikilt.wageningen-ur.nl/nutraceuticals  
 54
 
 
Exploitation and regulation of plants genetically modified to express nutraceuticals and 
pharmaceuticals  
http://www.rikilt.wageningen-ur.nl/nutraceuticals  
 55
7. General Conclusions  
 
7.1. Definitions 
 
?? A functional food is similar in appearance to, or may be, a conventional food, is 
consumed as part of a usual diet, and is demonstrated to have physiological 
benefits and/or reduce the risk of chronic disease beyond basic nutritional 
functions (Health Canada working definition). 
?? A nutraceutical is a product isolated or purified from foods that is generally sold 
in medicinal forms not usually associated with food and demonstrated to have a 
physiological benefit or provide protection against chronic disease (Health Canada 
working definition). 
?? A pharmaceuticals is a single, well-defined medicinal and therapeutic compound 
that is administered with the purpose to cure, prevent, or diagnose disease. Similar 
compounds for veterinary application are also categorized to pharmaceuticals. 
 
7.2. Biosafety considerations 
 
Concerning production of pharmaceuticals and nutraceuticals transgenically in (crop) 
plants, the specific characteristics of the plant and the recombinant compounds, the 
culture requirements, and the (national and international) guidelines and regulations 
make each production system an individual case. Biosafety assessments therefore 
needs to be carried out on a 'case-by-case' basis. For pharmaceuticals and 
nutraceuticals and their producing crops, a case should be considered to include the 
entire production chain from agricultural production towards the aimed effect of the 
ultimate product in human or animal. 
 
7.3. Regulatory options 
 
Out-doors cultivation- and market introduction- of genetically modified plants in the 
EU require a more extensive risk assessment than in-doors cultivation (“contained 
use”). In addition, out-doors cultivation and marketing will require “post market 
surveillance” under the recently adopted amendments to EU legislation. No specific 
guidelines have been developed, however, on how to carry out such a surveillance. In-
doors cultivation of a genetically modified crop and processing to non-viable products 
would help to circumvent some of the legal requirements for out-door cultivation, 
such as post market surveillance and field testing. The additional costs for cultivation 
in, for example, greenhouses should therefore be waged against the additional time 
and expenses spent on the preparation of dossiers (e.g. field trials, toxicology) for 
approval of out-doors cultivation. The possibilities for cultivation in greenhouses are 
discussed below. 
 
With regard to the possible food- and feed- applications (in the broadest meaning) the 
regulatory options appeared most attractive to us for “functional foods”, “functional 
feed”, and “nutraceuticals”: 
?? Functional foods:  
EU 
The most attractive appear to be non viable products that are substantially 
equivalent to conventional products on the market. Such products should either 
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be imported or produced from in-house cultivated plants within the same facility. 
The derived food product may follow the short-cut “notification” route for novel 
foods (Figure 2). 
 
USA 
The food components introduced or altered by the genetic modification should 
preferably be identical to previously approved “GRAS” substances (generally 
recognised as safe) or “food additives” to avoid lengthy approval procedures for 
truly novel components. In addition, safe foods and food ingredients may find 
application as “medical food” with less stringent requirements for labelling and 
health-related claims. 
 
An additional opportunity is to market the functional food as a food supplement 
in the USA. Ingredients of such supplements need not be GRAS, but the 
manufacturer should be able to prove their safety on request. For novel 
supplement ingredients, manufacturers should file a notification supported by 
safety data to the FDA 75 days prior to marketing. Although less “substance 
disease” claims are permitted than for foods, it is possible to attach “qualified” 
claims to these products. 
 
?? Functional feed: 
EU 
Non viable products from genetically modified plants are exempt from animal 
feed evaluation under the EU legislation pertaining to such plants. Currently a 
voluntary notification procedure for these non viable products exists in The 
Netherlands. This situation will likely change in the near future as proposed EU 
legislation on Novel Feeds will also cover non viable products for animal feed 
purposes. 
 
 
USA 
Safety requirements for animal feeds resemble those for food. Given the low 
added value for animal feeds in general, efforts to attain a safety status for food, 
with higher added value, may turn out more rewarding. 
 
?? Nutraceutical: 
Food purposes 
Nutraceuticals may be used as food ingredients (see “functional foods”). In 
addition, nutraceuticals may serve as food additives in the EU and USA, which is 
an attractive option if they are equivalent to food additives that have been 
previously found safe; otherwise, elaborate safety testing of the envisioned food 
additive will be required. 
 
Feed purposes 
Nutraceuticals can be used either as feed ingredients (see “functional feeds”) or 
as feed additives. 
 
No special requirements have been made for feed additives derived from 
genetically modified organisms in legislation, contrary to feed and feed 
ingredients. Feed additives may be an attractive option if the chosen (purified) 
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additive has previously been approved, because otherwise extensive toxicity- and 
efficiency- testing will be required. Whereas the presence in feed additives of 
DNA containing antibiotic resistance marker genes should be avoided in the EU, 
this may still be allowed for previously approved marker genes in the USA. 
 
In conclusion, most attractive for food- and feed-purposes appear purified products 
from genetically modified plants that are equivalent to conventional products. Their 
equivalence to existing products and their non viable nature will simplify the safety 
evaluation procedure. In addition, applications with high added value, such as 
“medical foods”, “food additives”, and “feed additives” appear feasible. 
 
With regard to pharmaceuticals, American regulations for biotechnology-derived 
medicines may be less demanding than EU regulations. The EU namely requires that 
any biotechnology-derived medicine be evaluated in full. In the USA, shorter 
procedures are possible in case of “bio-equivalence” to a previously approved 
“generic” medicine, though this may not apply to “biologics”. 
 
7.4. Options for contained culture 
 
Production of pharmaceuticals and nutraceuticals in GMOs in greenhouses is bound 
by special rules related to the transgenic status of the plants and according to the 
guidelines for GAP. As a result of GAP and GMO legislation, special demands need 
to be met with regard to the methods for plant production and to the required 
greenhouse facilities. PK-I and PK-II conditions can easily be introduced in most 
greenhouses. GAP demands that extra rooms for primary processing, packaging and 
storage are made. PK-III conditions require substantial investments.  
 
The type of greenhouse (PK-I, PK-II or PK-III) that needs to be used depends on the 
inserted gene, the plant species involved and its biological characteristecs (especially 
related to pollination). Careful selection of especially the plant species may overcome 
the need for PK-III facilities. COGEM gives detailed information about the 
containment level needed for greenhouses for GMOs. 
 
7.5 Conclusions on the case: Crop producing recombinant FSH 
 
The least burdensome option for the purified recombinant follicle stimulating 
hormone (rFSH) appears to be its use as reference material for pregnancy testing, for 
which limited clinical testing is required in the USA. 
 
Most appealing option 
 
?? Use as reference material for pregnancy tests in the USA. 
 
 
Note: As this report was being completed, the European Commission released a 
proposal for a new EU Regulation on genetically modified foods and animal feed, as 
well as on the traceability and labelling of these foods and feed (EC, 2001bc). Among 
the proposed changes to the existing EU legislation are: 
?? Documenting the use of genetically modified foods and feed throughout the 
entire production chain. 
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?? Labelling of all products derived from genetically modified organisms, 
including, among others: 
o Foods and animal feeds without detectable traces of foreign DNA or protein. 
o Food- and feed- additives. 
?? Abolishment of the “notification” short cut procedure for novel foods. 
?? Premarket evaluation of non viable animal feed similar to viable feed. 
?? Post market surveillance for genetically modified foods and feed to detect 
unforeseen long term effects. 
These changes, if they are indeed adopted, will diminish the attractiveness of the 
options described above for the EU. An alternative option for a functional food or 
nutraceutical in the EU may be their marketing as food supplements, which are not 
mentioned in the European Commission’s proposal. No harmonised EU legislation, 
however, exists on food supplements yet. 
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